Protective Antigens for the Control of Ixodes Species Infestations by Fuente, Jose de la et al.
c12) United States Patent 
de la Fuente et al. 
(54) PROTECTIVE ANTIGENS FOR THE 
CONTROL OF IXODES SPECIES 
INFESTATIONS 
(75) Inventors: Jose de Jesus de la Fuente, Stillwater, 
OK (US); Katherine M. Kocan, 
Perkins, OK (US); Consuelo 
Garcia-Almazan, Stillwater, OK (US); 
Jose Carlos Garcia-Garcia, Stillwater, 
OK (US); Edmour F. Blouin, Perkins, 
OK (US) 
(73) Assignee: The Board of Regents for Oklahoma 
State University, Stillwater, OK (US) 
( *) Notice: Subject to any disclaimer, the term of this 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 490 days. 
This patent is subject to a terminal dis-
claimer. 
(21) Appl. No.: 10/425,563 
(22) Filed: 
(65) 
Apr. 29, 2003 
Prior Publication Data 
US 2004/0022795 Al Feb. 5, 2004 
Related U.S. Application Data 
(60) Provisional application No. 60/376,251, filed on Apr. 
29, 2002. 
(51) Int. Cl. 
C07H 21104 (2006.01) 
A0JN 25100 (2006.01) 
(52) U.S. Cl. ...................................... 536/23.5; 424/405 
( 58) Field of Classification Search ... ... ... ... .. . 536/23 .5; 
424/405 
See application file for complete search history. 
V :-------A~• • 
H8 
GB__..• .. 
E8 -.i • 
DB 




















I 1111111111111111 11111 111111111111111 111111111111111 11111 111111111111111111 
flil 
US007214784B2 
(IO) Patent No.: US 7,214,784 B2 
*May 8, 2007 (45) Date of Patent: 
(56) References Cited 
U.S. PATENT DOCUMENTS 
4,447,537 A 5/1984 Yunker et al. .............. 435/235 
5,344,645 A 9/1994 Wikel ...................... 424/265.1 
5,587,311 A 12/1996 Cobon et al. ............ 435/240.2 
6,235,283 Bl 5/2001 Cobon et al. ............ 424/185.1 




FOREIGN PATENT DOCUMENTS 
WO 01/40469 6/2001 
WO O 1/80881 Al 11/2001 
WO 03/093416 A2 11/2003 
OTHER PUBLICATIONS 
Result No. 3 from a search of the EST database on May 12, 2006, 
alignment of SEQ ID No. 3 with a polynucleotide from the tick 
Ornithodoros porcinus porcinus, EST database record No. 
CB722011, contributed by Neilan et al., "Sequence analysis of 
Ornithodoros porcinus porcinus whole tick cDNA libraries," 
unpublished, Apr. 10, 2003.* 
(Continued) 
Primary Examiner-Jon Weber 
Assistant Examiner-Rosanne Kasson 
(74)Attorney, Agent, or Firm-Fellers, Snider, Blankenship, 
Bailey & Tippens 
(57) ABSTRACT 
Protective antigens against infestations with Ixodes spp. 
ticks, gene sequences and encoded proteins for such anti-
gens, related vaccines and methods useful to induce an 
immune response, which are protective to interfere with 
infestations by Ixodes spp. ticks are presented. 
5 Claims, 4 Drawing Sheets 






0 5 10 15 20 25 30 35 40 .. .. 
Number of tick larvae 
US 7,214,784 B2 
Page 2 
OTHER PUBLICATIONS 
Alberti E, Acosta A, Sarmiento ME, Hidalgo C, Vidal T, Fachado A, 
Fonte L, Izquierdo L, Infante JF, Finlay CM, Sierra G. Specific 
cellular and humoral immune response in Balb/c mice immunised 
with an expression genomic library of Trypanosoma cruzi. Vaccine 
1998; 16: 608-12. 
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local 
alignment search tool. J Mo! Biol 1990; 215: 403-10. 
Barry MA, Lai WC, Johnston SA. Protection against mycoplasrna 
infection using expression-library immunization. Nature 1995; 377: 
632-5. 
Black WC 4th, Piesman J. Phylogeny of hard- and soft-tick taxa 
(Acari: Ixodida) based on mitochondrial 16S rDNA sequences. Proc 
Natl Acad Sci US A 1994; 91: 10034-8. 
Brayton KA, Vogel SW, Allsopp BA. Expression library immuni-
zation to identify protective antigens from Cowdria ruminantium. 
Ann NY Acad Sci 1998; 849: 369-71. 
Cassataro J, Velikovsky CA, Giambartolomei GH, Estein S, Bruno 
L, Cloeckaert A, Bowden RA, Spitz M, Fossati CA. Immunogenic-
ity of the Bruce/la melitensis recombinant ribosome recycling 
factor-homologous protein and its cDNA. Vaccine 2002; 20: 1660-
9. 
de la Fuente J, Rodriguez M, Garcia-Garcia JC. Immunological 
control of ticks through vaccination with Boophilus microplus gut 
antigens. Ann NY Acad Sci 2000; 916: 617-21. 
de la Fuente J, Rodriguez M, Montero C, Redondo M, Garcia-
Garcia JC, Mendez L, Serrano E, Valdes M, Enriquez A, Canales M, 
Ramos E, Boue 0, Machado H, Lleonart R. Vaccination against 
ticks (Boophilus spp.): the experience with the Bm86-based vaccine 
Gavac. Genet Anal 1999; 15: 143-8. 
de la Fuente J, Rodriguez M, Redondo M, Montero C, Garcia-
Garcia JC, Mendez L, Serrano E, Valdes M, Enriquez A, Canales M, 
Ramos E, Boue 0, Machado H, Lleonart R, de Armas CA, Rey S, 
Rodriquez JL, Artiles M, Garcia L. Field studies and cost-effec-
tiveness analysis of vaccination with Gavac against the cattle tick 
Boophilus microplus. Vaccine 1998; 16: 366-73. 
De Rose R, McKenna RV, Cobon G, Tennent J, Zakrzewski H, Gale 
K, Wood PR, Scheerlinck JP, Willadsen P. Bm86 antigen induces a 
protective immune response against Boophilus microplus following 
DNA and protein vaccination in sheep. Vet Immunol Immunopathol 
1999; 71: 151-60. 
de Vos S, Zeinstra L, Taoufik 0, Willadsen P, Jongejan F. Evidence 
for the utility of the Bm86 antigen from Boophilus microplus in 
vaccination against other tick species. Exp Appl Acarol 2001; 25: 
245-61. 
Drew DR, Lightowlers M, Strugnell RA. Vaccination with plasmid 
DNA expressing antigen from genomic or cDNA gene forms 
induces equivalent humoral immune responses. Vaccine 1999; 18: 
692-702. 
Elad D, Segal E. Immunogenicity in calves of a crude ribosomal 
fraction of Trichophyton verrucosum: a field trial. Vaccine 199 5; 13: 
83-7. 
Estrada-Pena A, Jongejan F. Ticks feeding on humans: a review of 
records on human-biting Ixodoidea with special reference to patho-
gen transmission. Exp Appl Acarol 1999; 23: 685-715. 
Garcia-Garcia JC, Gonzalez IL, Gonzalez DM, Valdes M, Mendez 
L, Lamberti J, D' Agostino B, Citroni D, Fragoso H, Ortiz M, 
Rodriguez M, de la Fuente J. Sequence variations in the Boophilus 
microplus Bm86 locus and implications for immunoprotection in 
cattle vaccinated with this antigen. Exp Appl Acarol 1999; 23: 
883-95. 
Kofta W, Wedrychowicz H. c-DNA vaccination against parasitic 
infections: advantages and disadvantages. Vet Parasitol 2001; 100: 
3-12. 
Li you N, Hamilton S, Elvin C, Willadsen P. Cloning and expression 
of ecto 5 '-nucleotidase from the cattle tick Boophilus microplus. 
Insect Mo! Biol 1999; 8: 257-66. 
Liyou N, Hamilton S, Mckenna R, Elvin C, Willadsen P. Localiza-
tion and functional studies on the 5 '-nucleotidase of the cattle tick 
Boophilus microplus. Exp Appl Acarol 2000; 24: 235-46. 
Manoutcharian K, Terrazas LI, Gevorkian G, Govezensky T. Pro-
tection against murine cysticercosis using cDNA expression library 
immunization. Immunol Lett 1998; 62; 131-6. 
Melby PC, Ogden GB, Flores HA, Zhao W, Geldmacher C, Biediger 
NM, Ahuja SK, Uranga J, Melendez M. Identification of vaccine 
candidates for experimental visceral leishmaniasis by immunization 
with sequential fractions of a cDNA expression library. Infect 
Immun 2000; 68: 5595-602. 
Moore RJ, Lenghaus C, Sheedy SA, Doran TJ. Improved vectors for 
expression library immunization-application to Mycoplasma 
hyopneumoniae infection in pigs. Vaccine 2001; 20: 115-20. 
Mulenga A, Sugimoto C, Onurna M. Issues in tick vaccine devel-
opment: identification and characterization of potential candidate 
vaccine antigens. Microbes Infect 2000; 2: 1353-61. 
Munderloh UG, Wang YLM, Chen C, Kurtti TJ. Establishment, 
maintenance and description of cell lines from the tick Ixodes 
scapularis. J Parasitol 1994; 80: 533-43. 
Nuttall PA. Pathogen-tick-host interactions: Borrelia burgdorferi 
and TBE virus. Zentralbl Bakteriol 1999; 289: 492-505. 
Parola P, Raoult D. Tick-borne bacteriol diseases emerging in 
Europe. Clin Microbiol Infect 2001; 7: 80-3. 
Silva CL. The potential use of heat-shock proteins to vaccinate 
against mycobacterial infections. Microbes and Infection 1999; 1: 
429-35. 
Singh RA, Wu L, Barry MA. Generation of genome-wide CDS T 
cell responses in HLA-A*0201 transgenic mice by an HIV-1 
ubiquitin expression library immunization vaccine. J Immunol 
2002; 168: 379-91. 
Smooker PM, Setiady YY, Rainczuk A, Spithill TW. Expression 
library immunization protects mice against a challenge with virulent 
rodent malaria. Vaccine 2000; 18: 2533-40. 
van Drunen Littel-van den Hurk S, Loehr BI, Babiuk LA. Immu-
nization of livestock with DNA vaccines; current studies and future 
prospects. Vaccine 200 l; 19: 2474-9. 
Wikel SK, Rarnachandra RN, Bergman DK, Burkot TR, Piesman J. 
Infestation with pathogen-free nymphs of the tick Ixodes scapularis 
induces host resistance to transmission of Borrelia burgdorferi by 
ticks. Infect Immun 1997; 65: 335-8. Willadsen P. Novel vaccines 
for ectoparasites. Vet Parasitol 1997; 71: 209-22. 
Willadsen P, Jongejan F. Immunology of the tick-host interaction 
and the control of ticks and tick-borne diseases. Parasitol Today 
1999; 15: 258-62. 
Alamzan, C., Kocan, K.M., Bergman, D.K., Garcia-Garcia, J.C., 
Blouin, E.F., de la Fuente, J., "Identification of protective antigens 
for the control of Ixodes scapularis infestations using cDNA expres-
sion library immunization", Vaccine 2003; 21: 1492-1501. 
De La Fuente, J., Kocan, K.M., "Advances in the identification and 
characterization of protective antigens for recombinant vaccines 
against tick infestations", Expert Rev. Vaccines 2003; 2(4): 583-593. 
Alamzan, C., Kocan, K.M., Bergman, D.K., Garcia-Garcia, J.C., 
Blouin, E.F., de la Fuente, J., "Characterization of genes transcribed 
in an Ixodes scapularis cell line that were identified by expression 
library immunization and analysis of expressed sequence tags", 
Gene Therapy Molecular Biology, 2003, vol. 7: 43-59. 
Alamazan, et al.; Characterization of three Ixodes scapularis cDNAs 
protective against tick infestations; Vaccine, Butterworth Scientific. 
Guildford, GB, vol. 23, No. 35, Aug. 15, 2005, pp. 4403-4416. 
Almazan, et al.; "Vaccination with recombinant tick antigens for the 
control of Ixodes scapularis adult infestations"; Vaccine, But-
terworth Scientific. Guildford, GB, vol. 23, No. 46-47; Nov. 16, 
2005, pp. 5294-5298. 
Search report issued by the European Patent Office in Application 
No. 05256580.1; Applicant: The Board of Regents of Oklahoma 
State University, Mar. 22, 2006. 
PCT International Search Report for PCT/US03/13229, Feb. 11, 
2005. 
Das et al., "Salp25D, an Ixodes scapularis Antioxidant, Is 1 of 14 
Immunodominant Antigens in Engorged Tick Salivary Glands," 
published Sep. 28, 2001, The Journal of Infectious Diseases 2001; 
184:1056-64. 
Almazan et al., "Identification of protective antigens for the control 
of Ixodes scapularis infestations using cDNA expression library 
US 7,214,784 B2 
Page 3 
immunization," Vaccine, Butlerworth Scientific, Guidford, GB, vol. 
21, No. 13-14, Mar. 28, 2003, pp. 1492-1501. 
Almazan et al., "Characterisation of genes transcribed in a Ixodes 
scapularis cell line that were identified by expression library immu-
nization and analysis of expressed sequence tags," Gene Therapy 
and Molecular Biology, vol. 7. Jun. 2003, pp. 43-59. 
* cited by examiner 










DETERMINATION OF TICK 
INFESTATION. 
I 


















DETERMINATION OF TICK 
INFESTATION; EVALUATION OF 
MOLTING 
I 
SELECTION OF PROTECTIVE 
CDNAPOOLS 
IMMUNIZATION; CHALLENGE; 





U.S. Patent May 8, 2007 Sheet 2 of 4 US 7,214,784 B2 
Inhibition of tick infestation(%) 
V -I 
AS * flil H4 * m G4 * iJm F4 * 
E4 * all 
D4 * fiJ C4 
B4 * m 
A4 iEJ 
H3 * ~ 
G3 
m F3 * 
E3 ti 
D3 * ~ 
C3 IJ 
B3 * m A3 * ~ 
H2 ** m G2 
F2 
E2 
D2 * Fi 
C2 * ~ B2 * ~ A2 * m H1 * !!Ii G1 * F1 * ~ E1 * m 
01 m 
C1 ** 
B1 * riil A1 ~ 
0 5 10 15 20 25 30 35 40 45 50 









































. ** m . * 
* . 






* : ** * 
* . . 
GS ~ 
~~ j-:•::::::::::,=:•*:H_=, :-*:-.::•'=•*11-.~1 •**a---ilil] 
0 5 10 15 20 
Sheet 3 of 4 US 7,214,784 B2 










25 30 35 40 45 50 
































































US 7,214,784 B2 
1 
PROTECTIVE ANTIGENS FOR THE 
CONTROL OF IXODES SPECIES 
INFESTATIONS 
2 
drug resistant ticks that result from repeated acaricide appli-
cation (de la Fuente et al., 1998; Garcia-Garcia et al., 1999). 
Anti-tick vaccines also allow for inclusion of multiple 
antigens in order to target a broad range of tick species and 
CROSS REFERENCE TO RELATED 
APPLICATION 
5 for incorporation of pathogen-blocking antigens. 
This application claims the benefit of copending U.S. 
Vaccination with DNA and cDNA molecules has been 
used to induce a protective immune response against B. 
microplus and several pathogens in laboratory animals and 
livestock (De Rose et al., 1999; Drew et al., 1999; van Provisional Patent Application Ser. No. 60/376,251 filed 
Apr. 29, 2002. 
BACKGROUND OF THE INVENTION 
1. Technical Field 
10 Drunen Littel-van den Hurk et al., 2001; Kofta and Wedry-
chowicz, 2001 ). A new technique, expression library immu-
nization (ELI) in combination with sequence analysis pro-
vides an alternative approach for identification of potential 
vaccine antigens based on rapid screening of the expressed 
genes without prior knowledge of the antigens encoded by 
cDNA clones. ELI was first reported for Mycoplasma pul-
monis (Barry et al., 1995) and since then has been used for 
unicellular and multicellular pathogens and viruses (Man-
outcharian et al., 1998; Alberti et al., 1998; Brayton et al., 
The present invention relates to the identification of 15 
protective antigens against infestations with Ixodes spp. 
ticks, gene sequences and encoded proteins for such anti-
gens, related vaccines and methods useful to induce an 
immune response, which are protective to interfere with 
infestations by Ixodes spp. ticks. 20 1998; Melby et al., 2000; Smooker et al., 2000; Moore et al., 
2002; Singh et al., 2002). However, the identification of 
individual protective clones has not been reported and it is 
predicted that identification of protective antigens will be 
2. Background 
Ticks parasitize wild, domesticated animals and humans 
and transmit pathogens including fungi, bacteria, viruses and 
protozoan. Currently, ticks are considered to be second in 
the world to mosquitoes as vectors of human diseases, but 25 
they are considered to be the most important vector of 
pathogens in North America (Parola and Raoult, 2001). 
Ixodes spp. are distributed worldwide and act as vectors of 
human diseases caused by Borrelia burgdorferi (Lyme dis-
ease), Anaplasma phagocytophila (human granulocytic ehr- 30 
lichiosis ), Coxiella burnetti (Q fever), Francisella tularensis 
(tularemia), B. afzelii, B. lusitaniae, B. valaisiana and B. 
garinii, Rickettsia helvetica, R. japonica and R. australis, 
Babesia divergens and tick-borne encephalitis (TBE) and 
Omsk Hemorrhagic fever viruses (Estrada-Pena and Jonge- 35 
jan, 1999; Paro la and Raoult, 2001 ). Throughout eastern and 
southeastern United States and Canada, I. scapularis (the 
black legged tick) is the main vector of B. burgdorferi sensu 
stricto and A. phagocytophila (Estrada-Pena and Jongejan, 
1999; Parola and Raoult, 2001). 
more difficult as the complexity of the genome increases. 
Although several reports in the literature have demon-
strated by ELI that libraries can offer a degree of protection 
(Barry et al., 1995; Manoutcharian et al., 1998; Alberti et al., 
1998; Brayton et al., 1998; Melby et al., 2000; Smooker et 
al., 2000; Moore et al., 2002; Singh et al., 2002), none have 
applied ELI to arthropods and particularly to ticks. Several 
vaccines have been developed to protect humans against 
Ixodes-transmitted pathogens including TBE virus and B. 
burgdorferi. However, it is not clear whether these vaccines 
will protect against all pathogen strains and genotypes. The 
inclusion of tick immunogens in pathogen-specific vaccines 
could enhance their protective effect and increase efficacy 
(Nuttall, 1999). This transmission-blocking approach is sup-
ported by evidence that host resistance to ticks provides 
some protection against tick-borne transmission of viruses 
40 and B. burgdorferi (Wikel et al., 1997). Furthermore, vac-
cination against B. microplus has been demonstrated to 
contribute to the control of tick-borne diseases (de la Fuente 
et al., 1998; 1999). 
Control of tick infestations is difficult and often imprac-
tical for multi-host ticks such as Ixodes spp. Presently, tick 
control is effected by integrated pest management in which 
different control methods are adapted to one area or against 
one tick species with due consideration to their environmen- 45 
ta! effects. Recently, development of vaccines against one-
host Boophilus spp. has provided new possibilities for the 
identification of protective antigens for immunization 
against tick infestations (Willadsen, 1997; Willadsen and 
Jongejan, 1999; de la Fuente et al., 1999; 2000; de Vos et al., 50 
2001 ). The recombinant B. micro plus BM86 gut antigen 
included in commercial vaccine formulations TickGARD 
(Hoechst Animal Health, Australia) and Gavac (Heber Bio-
tee S. A., Havana, Cuba) also confers partial protection 
against phylogenetically related Hyalomma and Rhipiceph- 55 
alus tick genera (de la Fuente et al., 2000; de Vos et al., 
2001 ). However, immunization with BM86 failed to protect 
against the more phylogenetically distant Amblyomma spp. 
(de Vos et al., 2001). These results suggest that using Bm86 
or a closely related gene for the production of vaccines 60 
against Ixodes spp. or other tick genera phylogenetically 
distant from Boophilus spp. (Black and Piesman, 1994) 
could be impractical. Therefore, the screening for novel 
protective antigens is necessary to identify vaccine candi-
dates against infestations with these tick species of medical 65 
and veterinary importance. Control of ticks by vaccination 
would avoid environmental contamination and selection of 
SUMMARY OF THE INVENTION 
The present invention is based upon our identification by 
ELI and sequence analysis of protective cDNA clones 
against experimental infestations with I. scapularis. This is 
the first example of the application of ELI to arthropods and 
particularly to ticks. The protective antigens are homologous 
to endopeptidases, nucleotidases, chorion proteins, vitello-
genin receptors, peptidoglycan recognition proteins, 
glutamine-alanine rich proteins, ribosomal proteins, ~-adap-
tin, Beta-amyloid precursor protein, Block of proliferation 
(Bopl), lectins, chloride channels, RNA polymerases, 
ATPases and heat-shock proteins. These antigens induce an 
immune response in vaccinated hosts that either interferes 
with tick development or results in a pro-feeding activity, 
which could be due to the expression of cDNAs encoding for 
tick immunosuppressants, anticoagulants and other proteins 
with low antigenicity and a pro-feeding activity or they 
could encode for proteins homologous to host proteins with 
anti-tick activity, which neutralization results in a tick pro-
feeding activity. These protective antigens, although identi-
fied for I. scapularis, may be cross protective between 
US 7,214,784 B2 
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Ixodes species considering the high degree of conservation 
of gene sequences and protein function between species of 
the same genus. A 5'-nucleotidase was identified and char-
acterized in B. microplus by Liyou et al. (1999; 2000) but 
they did not assay its protection capacity. Although surpris- 5 
ing at first glance, the protection capacity of ribosomal and 
heat shock protein preparations has been previously docu-
mented in other organisms (Elad and Segal, 1995; Silva, 
1999; Melby et al., 2000; Cassataro et al., 2002) but never 
in ticks. The effect of cDNA vaccination on I. scapularis 10 
experimental infestations of mice was evidenced by the 
reduction of the number of engorged larvae, the retardation 
4 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a summary of the cDNA ELI approach used to 
identify protective antigens against I. scapularis infesta-
tions. 
FIG. 2A is a graph depicting the results of a primary 
screen of cDNA pools (A-H 1-4, AS) by ELI. V, control 
mice injected with 1 µg vector DNA alone. *a<0.01, 
**a<0.05 (Tukey's post-hoc test for pair comparisons after 
ANOVA). Number in boxes represent values for inhibition 
of tick infestation with respect to the control group. 
FIG. 2B is a graph depicting the results of a primary 
screen of cDNA pools (A6-A10, B-H 5-8) by ELI. V, 
control mice injected with 1 µg vector DNA alone. *a<0.01, 
**a<0.05 (Tukey's post-hoc test for pair comparisons after 
ANOVA). Number in boxes represent values for inhibition 
of tick infestation with respect to the control group. 
FIG. 3 is a graph depicting the results of a tertiary screen 
by ELI of cDNA sub-pools formed according to the pre-
of larval development, the inhibition of molting to nymphal 
stages and the appearance of visibly damaged larvae with 
15 
red coloration. These effects were also recorded in vaccina-
tion experiments with recombinant BM86 and BM95 
against infestations with B. microplus, including the red 
coloration in some ticks, attributed to blood leakage to the 
tick haemolymph (Garcia-Garcia et al., 2000). 
Thus, in one embodiment of the present invention there is 
provided cDNA sequences, protein encoding fragments 
thereof, and derived protein sequences for protective I. 
scapularis antigens comprising antigens homologous to 
endopeptidases, nucleotidases, chorion proteins, vitelloge- 25 
nin receptors, peptidoglycan recogmt10n proteins, 
glutamine-alanine rich proteins, ribosomal proteins, ~-adap-
tin, Beta-amyloid precursor protein, Block of proliferation 
(Bopl), lectins, chloride channels, RNA polymerases, 
20 dieted function of encoded proteins. Only groups with 
I~ 15% are shown (white bars). The number of engorged 
larvae per mouse is expressed as mean±SD (black bars). 
Control mice were injected with mitochondrial (MT) 
cDNAs. *P~0.05 (Student's t-test). 
ATPases and heat-shock proteins. 30 
DETAILED DESCRIPTION OF THE 
INVENTION 
Before explaining the present invention in detail, 1t 1s 
important to understand that the invention is not limited in 
its application to the details of the construction illustrated 
and the steps described herein. The invention is capable of 
other embodiments and of being practiced or carried out in 
a variety of ways. It is to be understood that the phraseology 
In another embodiment of the present invention there is 
provided a vaccine composition comprising the I. scapularis 
protective recombinant proteins and/or modified cDNAs 
separately or which may optionally be combined with adju-
vant to enhance the protection efficacy of vaccine prepara-
tions against Ixodes spp., wherein the vaccine composition 
further comprises a pharmaceutically acceptable carrier or 
diluent. The vaccine composition also may optionally be 
combined with tick-borne pathogen components to provide 
a means to control tick-borne infections, wherein the vaccine 
composition further comprises a pharmaceutically accept-
able carrier or diluent and adjuvant. 
35 and terminology employed herein is for the purpose of 
description and not of limitation. 
The present invention derives from the sequences set forth 
on the Sequence Listing attached hereto and incorporated 
herein. In particular, there is provided 25 separate and 
40 distinct sequences comprising 14 cloned cDNA molecules 
and 11 deduced amino acid sequences of encoded polypep-
tides, said sequences having been isolated and identified as 
possessing the asserted utility in accordance with the fol-
lowing described experimental methodology. In another embodiment of the present invention there is 
provided a method for inducing an immune response in a 45 
mammal to provide immune protection, which reduces or 
affects infestations by Ixodes spp. ticks and/or transmission 
of tick-borne pathogens, the method comprising administer-
ing to at-risk human population and mammalian reservoir an 
effective amount of a vaccine composition comprising the I. 50 
scapularis protective recombinant proteins and/or modified 
cDNAs alone or in combination with an adjuvant or tick-
borne pathogen components to provide a means to control 
tick infestations and to reduce transmission to humans of 
tick-borne infections, wherein the vaccine composition fur- 55 
ther comprises a pharmaceutically acceptable carrier or 
diluent. 
A better understanding of the present invention and its 
objects and advantages will become apparent to those skilled 
60 in this art from the following detailed description, wherein 
there is described only the preferred embodiment of the 
invention, simply by way of illustration of the best mode 
contemplated for carrying out the invention. As will be 
realized, the invention is capable of modifications in various 
obvious respects, all without departing from the scope and 65 
spirit of the invention. Accordingly, the description should 
be regarded as illustrative in nature and not as restrictive. 
EXAMPLE 1 
Construction of an I. scapularis cDNA Library and 
Screening for Protective Antigens by ELI 
Tick Cells 
Monolayers of IDES (ATCC CRL 1973) cells, originally 
derived from embryonic I. scapularis, were maintained at 
31 ° C. in L-15B medium supplemented with 5% foetal 
bovine serum, tryptose phosphate broth and bovine lipopro-
tein concentrate after Munderloh et al. (1994). Cells were 
subcultured at 1: 5-1: 10 when monolayers reached a density 
of approximately 107 cells/T-25 flask. Medium was replaced 
weekly. 
Library Construction 
A cDNA expression library was constructed in the vector 
pEXPl containing the strong cytomegalovirus CMVIE pro-
moter (Clontech). Because we planned to target the early 
larval stages of I. scapularis, we chose to construct our 
library from cultured embryonic I. scapularis IDES cells-
derived poly(A)+ RNA. The cDNA library contained 4.4x 
US 7,214,784 B2 
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106 independent clones and a titer of approximately 1010 
cfu/ml with more than 93% of the clones with cDNA inserts. 
The average cDNA size was 1.7 kb (0.5-4.0 kb). 
Primary Screen 
The overall schema for identification of protective anti-
gens through ELI, sequential fractionation and sequence 
analysis is shown in FIG. 1. 
Ninety-six LBA (master) plates containing an average of 
5 
41 (30---61) cDNA clones per plate were prepared. Replicas 10 
were made and clones from each plate were pooled, inocu-
lated in Luria-Bertani with 50 µg/ml ampicillin, grown for 2 
hr in a 96 wells plate and plasmid DNA purified from each 
pool (Wizard SV 96 plasmid DNA purification system, 
Promega, Madison, Wis., USA). BALB/c female mice, 5-6 15 
weeks of age at the time of first vaccination, were used. Mice 
were cared for in accordance with standards set in the Guide 
for Care and Use of Laboratory Animals. Mice were injected 
with a 1 ml tuberculin syringe and a 27 gauge needle at days 
0 and 14. Three mice per group were each immunized IM in 20 
the thigh with 1 µg DNA/dose in 50 µl PBS. Two groups of 
3 mice each were included as controls. One group was 
injected with 1 µg vector DNA alone and the second with 
saline only. Two weeks after the last immunization mice 
were infested with 100 I. scapularis larvae per mouse'. Ticks 25 
were artificially reared at the Oklahoma State University tick 
rearing facility by feeding larvae on mice, nymphs on rabbits 
and adults on sheep and using for infestation in our experi-
n:ients the larvae obtained from the eggs oviposited by a 
smgle female. Twelve hours after tick infestation, larvae that 30 
did not attach were counted to calculate the number of 
attached larvae per mouse and mice were transferred to new 
cages. Replete larvae dropping from each mouse were 
collected daily and counted during 7 days. The inhibition of 
tick infestation (I) for each test group was calculated with 35 
respect to vector-immunized controls as [1-(<RL>n/ 
<RL>cx<RL>ic/<RL>in)]xl00, where <RL>n is the aver-
age number of replete larvae recovered per mouse for each 
test group, <RL>c is the average number of replete larvae 
recovered per mouse for control group, <RL>ic is the 40 
average number of larvae attached per mouse for control 
group, and <RL>in is the average number oflarvae attached 
per mouse for each test group. 
Pools of 41 (30-61) I. scapularis cDNA clones were 
screened by ELI. Only 33 cDNA pools and controls were 45 
analyzed per experiment. The average tick infestation level 
was 50±13 and 56±15 and 56±15 and 54±18 larvae/mouse 
for cDNA immunized and control mice, respectively 
(P>0.05) (Table 1 ). The average number of engorged larvae 
recovered per mouse was 9±3 and 13±4 in the cDNA- 50 
immunized mice and 16±4 and 17±3 in the control vector-
immunized group (P<0.05) (Table 1). No reduction was 
observed in the number of larvae collected from mice that 
received the vector DNA compared to saline-immunized 
controls. The maximum number of engorged larvae was 55 
collected 3 to 4 days after infestation. However, in mice 
immunized with cDNA pools B5, AS and Al0 (FIG. 2) a 
retardation of larval development in 1 to 2 days was 
recorded. The average inhibition of tick infestation (I) was 
49±28% and 30±22% (Table 1). After two experiments 60 
covering the analysis of 66 pools (2705 clones), 9 protective 
pools (351 clones) were selected producing an inhibition of 
tick infestation E:';60% (FIGS. 2A and 2B and Table 1). 
When we started these experiments, we planed to screen 
~ver 4000 cDNA clones considering the complexity of the 65 
tick genome. However, to our surprise 9 protective cDNA 
pools were identified after screening 66 pools containing 
6 
2705 cDNA clones. This result probably reflects the possi-
bility of interfering with tick infestations at many different 
levels that involve a Pleiades of gene products. Results from 
vaccination experiments against ticks employing recombi-
nant antigens support this view (reviewed by Mulenga et al., 
2000). Because of the complexity of the screening procedure 
in mice vaccinated and challenged with tick larvae, it was 
difficult to work with more than 9 protective cDNA pools. 
Therefore we did not continue screening new cDNA pools 
and focused our attention on the 9 pools selected after the 
primary screen. 
Secondary Screen 
The secondary screen was done to verify the protective 
capacity of the cDNA pools selected after the primary screen 
(FIGS. 2A and 2B). After the primary screen of 66 cDNA 
pools (2705 clones), 9 pools with 1~60% were selected for 
the secondary screen (re-screening) employing 5 mice per 
group as described above. Engorged larvae were kept for 
molting in a 95% humidity atmosphere. Molting of engorged 
larvae was evaluated by visual examination of tick nymphs 
under a stereomicroscope 34 days after last larval collection. 
The inhibition of molting (M) for each test group was 
calculated with respect to vector-immunized controls as 
[1-(MLn/MLcxRLc/RLn)]xl00, where MLn is the number 
of nymphs for each test group, MLc is the number of 
nymphs for the control group, RLc is the number of larvae 
recovered for the control group, and RLi is the number of 
larvae recovered for each test group. Control mice were 
immunized with the negative (I=0%) F2 cDNA pool or 
saline only. A group was included immunized SC with two 
doses of 100 µg of total IDES tick cell proteins per dose in 
Freund's incomplete adjuvant. 
All 9 protective cDNA pools gave positive results in the 
secondary screen (data not shown). The tick infestation 
levels were higher in this experiment (average 85±6 and 
84±3 larvae/mouse for cDNA-immunized and control mice 
respectively; P>0.05). Nevertheless, the average number of 
engorged larvae recovered per mouse was 39±7 and 26±6 
for control and cDNA-immunized mice, respectively 
(P<0.05). The group immunized with total IDES tick cell 
proteins was protected with 1=33%. Again, no reduction was 
observed in the number of larvae collected from mice that 
received the control cDNA (F2 negative pool after the 
primary screen; FIG. 2A) compared to saline-immunized 
controls. 
In the secondary screen, molting of engorged larvae was 
evaluated after 34 days. Molting was affected in all but one 
test cDNA-immunized group. Inhibition of molting in test 
cDNA-immunized mice compared to the control cDNA-
immunized group varied from 0% to 12% (6±4%). The 
inhibition of molting was higher than 50% only in the larvae 
collected from mice immunized with cDNA pools B5 and 
AlO, which showed a retardation oflarval development in 1 
to 2 days as in the primary screen. No differences were 
observed between control cDNA and saline-immunized 
mice. Among the larvae that did not molt to nymph, some 
were visibly damaged and presented a strong red coloration. 
The percent of red larvae in cDNA-immunized mice varied 
between 3% to 18% (7±5%) while in the saline and control 
cDNA-immunized groups red larvae represented the 6% and 
4%, respectively. 
Tertiary Screen 
For the tertiary screen, 64 clones were grouped in 16 
sub-pools each containing 1 to 17 plasmids according to the 
predicted function of encoded proteins ( e.g., all the plasmids 
that encoded histone proteins were grouped together) and 
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used with 4 sub-pools containing 182 clones of unknown 
function or with sequences without homology to sequence 
databases to immunize 4 mice per group. Mice were immu-
nized with 0.3 µg/plasmid/dose in 50 µl PBS and evaluated 
as described above. Control mice were immunized with a 5 
pool of 20 plasmids containing mitochondrial cDNAs. 
Tick infestation levels were similar in all test groups 
(72±2 larvae/mouse) and in control mice (69±2 larvae/ 
mouse) (P>0.05). The number of engorged larvae recovered 
per mouse was also similar between test (16±7) and control 10 
(14±6) mice (P>0.05). However, the groups immunized with 
cDNA sub-pools containing clones with putative endopep-
tidase, nucleotidase, ribosomal proteins, heat shock proteins, 
glutamine-alanine-rich proteins and 3 of the sub-pools with 
unknown function or with sequences without homology to 
15 
sequence databases had 1~15% (FIG. 3). Furthermore, 
among them, the groups immunized with sub-pools contain-
ing clones with a putative endopeptidase, nucleotidase and 
two of the cDNA sub-pools with unknown function or with 
sequences without homology to sequence databases resulted 
8 
including those containing similar sequences (Table 2). The 
protective clones included antigens homologous to endopep-
tidases, nucleotidases, chorion proteins, vitellogenin recep-
tors, peptidoglycan recognition proteins, glutamine-alanine 
rich proteins, ribosomal proteins, and heat-shock proteins. 
SUMMARY OF RESULTS 
The results obtained with the various protective clones 
identified in the Sequence Listing, along with certain 
selected expressed proteins, are summarized in Table 4. 
SEQ ID NO:1 denotes the clone designated 4E6, wherein 
the relevant protein encoding fragment has been identified as 
comprising residues 1-117, which encodes the polypeptide 
shown in SEQ ID NO: 2. 
SEQ ID NO:3 denotes the clone designated 4D8, wherein 
the relevant protein encoding fragment has been identified as 
comprising residues 80---575, which encodes the polypeptide 
shown in SEQ ID NO: 4. 
SEQ ID NO:5 denotes the clone designated 4F8, wherein 
the relevant protein encoding fragment has been identified as 
comprising residues 1-951, which encodes the polypeptide 
shown in SEQ ID NO: 6. 
in lower infestation levels compared to control mice 20 
(P~0.05) and g40% (FIG. 3). Clones homologous to 
chorion proteins, vitellogenin receptors, and peptidoglycan 
recognition proteins were selected for they potential protec- SEQ ID NO:7 denotes the clone designated 4G 11, 
wherein the relevant protein encoding fragment has been 
25 identified as comprising residues 1-697, which encodes the 
polypeptide shown in SEQ ID NO: 8. 
tion capacity in other stages of tick development. 
Statistical Analysis 
The number oflarvae attached per mouse and the number 
of engorged larvae recovered per mouse 7 days after infes-
tation were compared by Analysis of Variance (ANOVA) 
followed by a series of Tukey's post-hoc tests for pair 
comparisons between cDNA-immunized and control vector 
DNA-immunized mice (primary screen), and by Student's 
t-test between mice immunized with positive cDNA pools 
and the control negative F2 cDNA pool (secondary screen) 
or between test cDNA sub-pools-immunized and control 
mice immunized with mitochondrial cDNAs (tertiary 
screen). 
EXAMPLE 2 
Sequence Analysis of Protective Clones 
All the 351 cDNA clones in the 9 pools that resulted 
positive in the secondary screen were sequenced. DNA from 
individual clones in these pools was purified (Wizard SV 96 
plasmid DNA purification system, Promega) from the mas-
SEQ ID NO:9 denotes the clone designated 4D6, wherein 
the relevant protein encoding fragment has been identified as 
comprising residues 198-1025, which encodes the polypep-
30 tide shown in SEQ ID NO: 10. 
SEQ ID NO:11 denotes the clone designated 3El, 
wherein the relevant protein encoding fragment has been 
identified as comprising residues 3-578, which encodes the 
polypeptide shown in SEQ ID NO: 12. 
SEQ ID NO:13 denotes the clone designated lClO, 
35 wherein the relevant protein encoding fragment has been 
identified as comprising residues 1-1119, which encodes the 
polypeptide shown in SEQ ID NO: 14. 
SEQ ID NO:15 denotes the clone designated 3E10, 
wherein the relevant protein encoding fragment has been 
40 identified as comprising residues 51-1544, which encodes 
the polypeptide shown in SEQ ID NO: 16. 
SEQ ID NO:17 denotes the clone designated 4Fll, 
wherein the relevant protein encoding fragment has been 
identified as comprising residues 31-2295, which encodes 
45 the polypeptide shown in SEQ ID NO: 18. 
ter plate and partially sequenced. In most cases a sequence 
larger than 700 nucleotides was obtained. Nucleotide 
sequences were analyzed using the program AlignX (Vector 
NTI Suite V 5.5, InforMax, North Bethesda, Md., USA). 
BLAST (Altschul et al., 1990) was used to search the NCBI 50 
databases to identify previously cloned sequences that may 
have homology to those that we sequenced. Sequence analy-
SEQ ID NO:19 denotes the clone designated 3C12, 
wherein the relevant protein encoding fragment has been 
identified as comprising residues 6-332, which encodes the 
polypeptide shown in SEQ ID NO: 20. 
SEQ ID NO:21 denotes the clone designated 2C12, 
wherein the relevant protein encoding fragment has been 
identified as comprising residues 3-137, which encodes the 
polypeptide shown in SEQ ID NO: 22. sis allowed grouping the clones according to sequence 
identity to DNA databases and predicted protein function. 
The protective clones selected after the tertiary screen were 
fully sequenced. 
SEQ ID NOS: 22, 23 AND 24, denote, respectively, 
55 
clones 1A9, 182 and 4A4, each comprising a partial 
sequence with no associated polypeptide. 
Comparison to sequence databases permitted to identify 
sequence identity to previously reported genes with known 
function in 152 (43%) of the clones (Table 2). Fifty seven 
percent of the sequences were homologous to genes with 
unknown function or had no significant identity to previ- 60 
ously reported sequences (Table 2). Of the clones with 
sequence identity to genes with known function, 85% were 
homologous to arthropod sequences. Ninety-three clones 
(61%) contained sequences homologous to Drosophila 
melanogaster, 5 (3%) to other insects and 32 (21 %) to Ixodid 65 
tick species. Thirty percent of the clones were eliminated 
from further analysis based on their sequence identity, 
* * * * * 
As noted above, the present invention relates to the 
sequences identified in the Sequence Listing. More gener-
ally, the invention concerns the given cDNA sequences and 
any nucleotide sequence coding for a protein which is 
capable of eliciting an antibody or other immune response 
(e.g., T-cell response of the immune system) which recog-
nizes an epitope(s) of the amino acid sequences depicted in 
the Sequence Listing, including less than the full cDNA 
sequences and mutants thereof. Hence the nucleotide 
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sequence may encode a protein which is the entire antigen 
encoded by the variously identified bases, or a fragment or 
derivative of the antigen or a fusion product of the antigen 
or fragment and another protein, provided that the protein 
which is produced from such sequence is capable of eliciting 5 
an antibody or other immune response which recognizes an 
epitope(s) of the given amino acid sequences. 
10 
herein means that the vaccine prevents disease associated 
with a particular tick species or reduces the severity of the 
disease. 
The carrier employed in conjunction with vaccine may be 
any one of a wide variety of carriers. As representative 
examples of suitable carriers, there may be mentioned 
mineral oil, synthetic polymers, etc. Carriers for vaccines are 
well known in the art and the selection of a suitable carrier 
is deemed to be within the scope of those skilled in the art. 
As a result, the invention encompasses DNA sequences 
which encode for and/or express in appropriate transformed 
cells, proteins which may be the full length antigen, antigen 
fragment, antigen derivative or a fusion product of such 
antigen, antigen fragment or antigen derivative with another 
protein. 
10 ~:~:~ef~i:h~{: ::~t:~~:f;~:\~s i~s~::::~:;:d~pon the 
The present invention provides a method of immunizing 
a susceptible manmial, against infestations and disease 
caused by Ixodes species with the vaccine described above. 
For purposes of this invention, the vaccine is administered Proteins included within the present invention have an 
amino acid sequence depicted in the Sequence Listing. 
Other included proteins consist of a fragment of said 
sequence capable of eliciting an antibody or other immune 
response which recognizes an epitope(s) of the amino acid 
sequences depicted and a mutuant of said sequence capable 
of eliciting an antibody or other immune response which 
recognizes an epitope(s) of such amino acid sequences. 
15 in an effective amount. The vaccine may be administered by 
any of the methods well known to those skilled in the art, for 
example, by intramuscular, subcutaneous, intraperitoneal or 
intravenous injection. Alternatively, the vaccine may be 
administered intranasally or orally. It is also to be under-
The nucleotide sequences may be inserted into any of a 
wide variety of expression vectors by a variety of proce-
dures. Such procedures and others are deemed to be known 
20 stood that the vaccine may include active components, such 
as tick-borne pathogen components or adjuvants in addition 
to the antigen(s) or fragments hereinabove described. 
The host expressing the antigen may itself be used to 
deliver antigen to non-human animals, by introducing killed 
25 or viable host cells that are capable of propagating in the 
animal. Direct incorporation of the cDNA sequences into 
host cells may also be used to introduce the sequences into 
animal cells for expression of antigen in vivo. 
by those skilled in the art. Suitable vectors include chromo-
somal, nonchromosomal and synthetic DNA sequences; e.g., 
derivatives ofSV40; bacterial plasmids; phage DNAs; yeast 
plasmids; vectors derived from combinations of plasmids 
and phage DNAs, viral DNA such as baculovirus, vaccinia, 
adenovirus, fowl pox virus, pseudorabies, etc. The appro-
priate DNA sequence must be operatively linked in the 30 
vector to an appropriate expression control sequence(s) 
(promoter) to direct mRNA synthesis. As representative 
examples of such promoters, there may be mentioned LTR 
or SV 40 promoter, the E. coli lac or trp, the phage lambda 
PL promoter and other promoters known to control expres- 35 
sion of genes in prokaryotic and enkaryotic cells or their 
viruses. The expression vector also includes a non-coding 
sequence for a ribosome binding site for translation initia-
tion and a transcription terminator. The vector may also 
include appropriate sequences for amplifying expression. 40 
The vector containing the appropriate cDNA sequence as 
hereinabove described, as well as an appropriate promoter or 
control sequence, may be employed to transform an appro-
priate host to permit the host to express the protein. 
Examples of host organisms and cells include bacterial 45 
strains ( e.g., E. coli, Pseudomonas, Bacillus, Salmonella, 
etc.), fungi (e.g., yeasts and other fungi), animal or plant 
hosts (e.g., mouse, swine or animal and human tissue cells). 
The selection of the host is deemed to be within the scope 
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Primary screen of the I. scapularis cDNA library by ELI in mice. 
Number Average± SD Average± SD 
of pools number of number of 
screened larvae engorged 
(Number attached per larvae per 
of clones) mouseb mousec 
33 (1383) 50 ± 13 (33-80) 9 ± 3 (2-42) 
56 ± 13 (45-67) 16 ± 4 (5-27) 






39 ± 55% 
(-183-87%) 
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TABLE I-continued 
Primary screen of the I. scapularis cDNA library by ELI in mice. 
Number of 
Number Average± SD Average± SD Average± SD pools 
of pools number of number of inhibition of selected for 
screened larvae engorged tick the 
(Number attached per larvae per infestation secondary 
of clones) mouseb mousec (I/ screen 
54 ± 18 (36-73) 17 ± 3 (6-28) 
"Ninety six LBA plates containing an average of 41 cDNA clones per plate were prepared. Rep-
licas were made and clones from each plate were pooled, inoculated, grown for 2 hr in a 96 
wells plate and plasmid DNA purified from each pool for ELI. Three mice per group were each 
immunized IM twice with 1 µg DNA/dose in 50 µl PBS two weeks apart. Two groups of 3 mice 
each were included as controls. One group was injected with vector DNA and the second with 
saline only. 
bFifteen days after the last immunization, mice were infested with 100 1 scapularis larvae per 
mouse. Twelve hrs later, larvae that did not attach were counted to calculate the nwnber of 
attached larvae per mouse and mice were transferred to new cages. 
cEngorged larvae dropping from each mouse were collected daily and counted after 7 days. 
dThe inhibition of tick infestation (I) for each test group was calculated with respect to vector-
immunized controls as [1-(RLn/RLc x RLic/RLin)] x 100, where RLn is the average number of 
replete larvae recovered per mouse for each test group, RLc is the average number of replete 
larvae recovered per mouse for control group, RLic is the average number of larvae attached per 
mouse for control group, and RLin is the average nwnber of larvae attached per mouse for 
eachtest group. 
TABLE 2 30 
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TABLE 3-continued 
Classification of the clones in protective pools by putative protein function 
according to identity to sequence databases. 
Grouping of the clones according to the predicted function of 
encoded proteins in sub-pools for the tertiary screen. 
Putative protein Function Number of clones Sub-pool (No. of clones) Clone Pool" 
35 
Biosynthetica 2 3G9, 3G10 E3 
Catabolism 4 4Dll,4D12,4E7,4F7 Fl 
Cell adhesion 2 Membrane protein (7) 1D8, lDll, lEl0 D1 
Cell cycle" 2 2B12 Al0 
Cytoskeletal" 8 2H5 ES 
Defense 2 3C9 B4 
DNA structure or replicationa 3 40 3Gll E3 
Extracellular matrix 3 ATPase (6) 1A9, 1B2, 1C9 AS 
Endocytosis 2 2C9 Al0 
Energy metabolism 10 4A4 C3 
Homeostasis 2 4G12 Fl 
Morphogenetic 9 Cell channel/Transporter ( 5) 1F4 D1 
Mitochondrial" 34 45 2Hll ES 
Protein synthesis or processinga,b 34 4A12 C3 
RNA synthesis or processinga 7 4Gl0,4Gll Fl 
Heat-shock proteins 4 Early development-specific (4) 1C8 AS 
Signal transduction 16 3F4 E3 
Transport 8 4C7 C3 
Unknown 199 50 4G9 Fl 
G protein-coupled receptor (4) 2B7,2C12 Al0 
Total 351 2F12 ES 
4C9 C3 
aEliminated from further screening of protective antigens. Other clones Growth factor receptor (3) 2E8 BS 
were eliminated for containing similar sequences. 3B8,3C8 B4 
bExcept for ribosomal proteins. 
55 Lectin (3) 3E10 E3 
4B8,4C8 C3 
Vitellogenin (3) 1F12 D1 
TABLE 3 4A6 C3 
4G2 Fl 
Grouping of the clones according to the predicted function of Heat shock (3) lCl0 AS 
encoded proteins in sub-pools for the tertiary screen. 60 lFl0 D1 
Sub-pool (No. of clones) Clone Pool" 
3F6 E3 
EGF-like (2) 2H4 ES 
Ribosomal (17) 1A2,1A10,1Cll AS 4C10 C3 
1F6 D1 Secreted protein (2) 2F9 ES 
2B8 Al0 3C12 B4 
2F8, 2F10 ES 65 Glutamine-Alanine rich (2) 4D6, 4E6 Fl 
3A10,2C3,3D2,3D10 B4 Adaptin (1) 3El E3 
US 7,214,784 B2 
15 16 
TABLE 3-continued TABLE 4-continued 
Grouping of the clones according to the predicted function of 
encoded proteins in sub-pools for the tertiary screen. 5 
Summary of results with I. scapularis cDNA clones. 
Inhibition 












10 1A9, 1B2, 
4A4 
of tick Inhibition 
infestation of molting Efficacy 
Predicted Protein I(%) Mo/o E(%) 
RNA polymerase III -104*** ND ND 
ATPase -57*** ND ND 
acDNA pools refer to positive pools after primary and secondary screens 
(FIG. 2A and 2B). Mice were immunized with cDNA-containing expression plasmid DNA as 
described above (*) or with 100 µg/dose of recombinant protein expressed 
in E. coli (**). I, M and E were calculated as described above. ND, not 
TABLE 4 15 determined. 
Summary of results with I. scapularis cDNA clones. 
***Resulted in a pro-feeding activity. This effect could be due to the 
expression of cDNAs encoding for tick immunosuppressants, anticoagu-
lants and other proteins with low antigenicity and a pro-feeding activity. 
Alternatively, they could encode for proteins homologous to host proteins 



























































In view of the above, it will be seen that the several 
objectives of the invention are achieved and other advanta-
geous results attained. As various changes could be made in 
the above DNA molecules, proteins, etc. without departing 
25 from the scope of the invention, it is intended that all matter 
contained in the above description or shown in the accom-
panying drawings shall be interpreted as illustrative and not 
in a limiting sense. While the invention has been described 
with a certain degree of particularity, it is understood that the 
3E10 Mannose binding -48*/-10*** ND ND 
30 invention is not limited to the embodiment(s) set for herein 
for purposes of exemplification, but is to be limited only by 
the scope of the attached claim or claims, including the full 
range of equivalency to which each element thereof is 
entitled. 
lectin 
4Gll Chloride channel 38*** 30 57 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 25 
<210> SEQ ID NO 
<211> LENGTH: 349 
<212> TYPE: DNA 








<210> SEQ ID NO 2 
<211> LENGTH: 38 







<213> ORGANISM: Ixodes scapularis 












Met Glu Ile Ser Val Lys Pro Arg Pro Thr Lys Arg Lys Arg Lys Ala 







US 7,214,784 B2 
17 
-continued 
Ile Ile Ile Met Ala Arg Met Arg Thr Ala Phe Pro Thr Arg Ser Gly 
20 25 30 
Asn Ser Phe Ser Arg Thr 
35 
<210> SEQ ID NO 3 
<211> LENGTH: 2693 
<212> TYPE: DNA 
<213> ORGANISM: Ixodes scapularis 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (685) .. (685) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (1962) .. (1962) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<400> SEQUENCE: 3 
ggtttgtgct gcttggaaaa tccaccagga gcctgcaacc gcaaaaaagt tcatcatccg 60 
gagctaagcc tatcgcagga tggcttgcgc aacattaaag cgaacacacg attgggatcc 120 
gctgcatagt ccaaacggaa gatcgcccaa acgacggaga tgtatgcctt tgtcggtcac 180 
acaagcagcg actcccccaa caagggcaca ccaaatcaac ccttcaccct tcggtgaagt 240 
gccaccgaaa ttaacttcag aggagatagc ggccaacatt cgggaggaaa tgcgacgtct 300 
gcagcggcgc aagcagctct gcttctcgtc tcccctggag tcgggctccc cgtcggcgac 360 
tccccctgcg gccgattgcg gaccagcctc ccccacgggc ctgtcccccg ggggcctgct 420 
gtcgcccgtg cgcagggacc aacccctctt caccttccgc caggtggggc tcatctgcga 480 
gcgcatgatg aaggagcgcg agagccagat acgcgacgag tacgaccacg ttctgtctgc 540 
caagctggca gagcagtacg acacatttgt caagtttacg tacgaccaaa ttcagaagcg 600 
gtttgagggt gccactccaa gctatttgtc ataacatgat gggcatctgc aaacaagcaa 660 
ggaactttga gggtttgtgc taganggaag aaacccatgg tggggaagga cacaagacca 720 
acacttagac tcggcaagca agccagatcc tgtggggtgc ggggacgggg ggaatgagtc 780 
cagtggtgtc ttcggagttt ttttttttcc ttctcccttt ccctcgtctt ctttttggca 840 
caactcttta cggaactggt gtgcatccat tccccgaaag tgcaagagaa ggactcgcgg 900 
cggatcatct acggaggaag aagtgtgtat gcctttgtgc tttgggtctc cttttttttt 960 
tttttaaccg tcttgccatc tcgccataga agacctgtga tctagcaaac aaaggtgtgc 1020 
gaatgttatg caaaggttgg aagtcagttt gaaagtggag cgagagaaaa ttttgtatgc 1080 
tgagtatggt tagtcaccgt ttacttttca ggagggggat gactgaggaa cggagccgcc 1140 
ccaactctcg tttgtctttt atttttagga tactttctct gtggcgagaa tttgtgtgtg 1200 
catgcaagtt agcgagggta cgaggaaaag aagggttata aaatattctg ggtgagagct 1260 
gtagttcaac tggggggtgg gattgtaaag acctgcgggt accgagagga ccgcatgctc 1320 
tggctatatt acttgcattg agggggagga ggaatgctgg acctcgagca gagccagcaa 1380 
gtattttgga aaggaataaa aacaaaaatt ggcttagtgt acagatgtat aatatatatg 1440 
cactacaggg tgtgtgtgcc tcttgtatct tcccgtgcgt tgtgtccctc ttgcggcttg 1500 
cccatctgac aaccgcctgt gtacataggc caacgcaagt cttcagcatg gcaccctctt 1560 
ctttttcctt ttttttttct cataagtaat tttgaaggag agaatatttt gatttctaag 1620 
actcccaaaa catcaagtgc tctggtggtc ggaattctac aagtgcgaaa gttcctttct 1680 


















<210> SEQ ID NO 4 
<211> LENGTH: 184 


















<213> ORGANISM: Ixodes scapularis 
<400> SEQUENCE: 4 
US 7,214,784 B2 
-continued 
gtaggcctgt gacacttgca cagccgtgtt 
ataaaaactt gttatggaaa gagtgcatta 
tggaatgcat gcctgatgtg tgttgtgctt 
aaaggagctt anaatgcctt ctggcttttg 
ttgtcaatca cagtgcaaca tgcactttgt 
tgcagagttt gactaatttt tagtaatgct 
ttcatcaact cgtcgatcat tatgcatgtg 
atcacagttg cactgaggaa gcctggctta 
cgtattttcc agcataaagc tggtagtgta 
ccattgctgc cacaattcat gcatgaatga 
aaaactgatt tgaagtacca gtgtcctata 
attgtttacg gaaaaaagtg ataacattaa 
ttttccagga gaatttagac caggaggcac 
gacttggttt ttgtggaaat tagttctaaa 
gcattgccat tgtaatttgg ccattattag 
aaaaaaaaaa aaaaaaaaaa aaa 
Met Ala Cys Ala Thr Leu Lys Arg Thr His Asp Trp Asp Pro Leu His 
1 5 10 15 
Ser Pro Asn Gly Arg Ser Pro Lys Arg Arg Arg Cys Met Pro Leu Ser 
20 25 30 
Val Thr Gln Ala Ala Thr Pro Pro Thr Arg Ala His Gln Ile Asn Pro 
35 40 45 
Ser Pro Phe Gly Glu Val Pro Pro Lys Leu Thr Ser Glu Glu Ile Ala 
50 55 60 
Ala Asn Ile Arg Glu Glu Met Arg Arg Leu Gln Arg Arg Lys Gln Leu 
65 70 75 80 
Cys Phe Ser Ser Pro Leu Glu Ser Gly Ser Pro Ser Ala Thr Pro Pro 
85 90 95 
Ala Ala Asp Cys Gly Pro Ala Ser Pro Thr Gly Leu Ser Pro Gly Gly 
100 105 110 
Leu Leu Ser Pro Val Arg Arg Asp Gln Pro Leu Phe Thr Phe Arg Gln 
115 120 125 
Val Gly Leu Ile Cys Glu Arg Met Met Lys Glu 
130 135 
Arg Asp Glu Tyr Asp His Val Leu Ser Ala 
145 150 
Asp Thr Phe Val Lys Phe Thr Tyr Asp 
165 
Gly Ala Thr Pro Ser Tyr Leu Ser 
180 






Arg Glu Ser Gln Ile 
140 
Leu Ala Glu Gln Tyr 
160 



















<211> LENGTH: 1821 
<212> TYPE: DNA 
21 
<213> ORGANISM: Ixodes scapularis 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (1487) .. (1487) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (1595) .. (1595) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (1606) .. (1606) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (1623) .. (1623) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (1762) .. (1762) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (1789) .. (1789) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<400> SEQUENCE: 5 
US 7,214,784 B2 
-continued 
atggcgtcgt gtggagcatc agcgacgggt cctctcgtcc taagagtaat ttccaacact 60 
gttaaaatag ttaacagcgc cggaaagata atcaaggaca tcatgaacag tggaaacctc 120 
ggaatcgtcg aaaaggaagg catcaatgac ctgcaaacgg aggcagacag atctgttcag 180 
cgctgcattg tgacttcgct ctcgagacag ttcccaaaac tgacaataat tggtgaagag 240 
actctggagg agaaaaagat cagcgacgac tggatcatca ccgagcatga caaggatgtc 300 
ctggccactt ctctgccgga caacctgaag aacatcaaag aggaagattt ggtagtctgg 360 
gttgatcctc tggatggaac caaggagtac acacagggtt tcctggacca cgtgacgatc 420 
ctggtgggga ttgcggttga cggtaaggca gtgggtggag tgatccacca gccgtactac 480 
aactaccagg tggagaagga cgtctacaag cagggacgta ccatgtgggg cattgtcggc 540 
gtcggtgcct ttgggatctc gcgcattgcg cctccggaga acaagaggat catcactacg 600 
acgcgctccc attccagccc caccatcaac agctgcattg aagccatgaa tccggacgag 660 
gtgctgcgag ttggaggtgc cgggcacaag gtgctgctgt tgattgaggg caaggctcac 720 
gcttacgtgt ttcccagcaa agggtgcaag aaatgggaca cttgtgcccc cgaagcgatt 780 
cttcatgcca ctggcggcct tcttacagat gttcacggga acagattgga gtaccacaag 840 
gacgtggaac acgtcaatgc cggcggcgtt cttgccacct gcctgaagga acaacacgaa 900 
tggttcaaga accacattcc cgaagatgtc cgcaagacgc ttcctctatg agcaacctgc 960 
cgttgtccgt tgcgatcaca ctcaagtcgc gtttttcctt taactttgtg gtgatgcggt 1020 
tcaaagtctt atactattag tgttttggtg gtccaaatat tattactaaa aaaacccgga 1080 
gacatgggac acaaaaaaat ggaggggcgg gacaataagg tctcgaacac agctcgtaca 1140 
gaatttttta aaataatgtt gatttcaggt ttatttgtgg aaactctgaa attaaccgtt 1200 
atgtcattat ttgggttgtg ccgtttgaaa ttttatgaaa tacgtaatag ctgcacgcat 1260 
tttgcaggcc actcagctcc ttgaatgctc gatgcttgat gcttctgcca acattatttg 1320 
tatctcaagt ttttctacca caagaaacag taccctaaca ttttgaaata gtattactag 1380 
cttggatttt atctggtatg catatataag atctatggat gttcctaagg agggcatgaa 1440 
tttgaaacat accctgtcct taccaacctt caaacatttt tttttgngcc tgcttaaaag 1500 
22 
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23 
-continued 
cacttacatt gcttgatcgt tgaattaatt 
attaaggaaa tgagatcgat cttgagcttg 
canacctaat gcttaatgca acaataatta 
gcaagcagat gccaatgctt ctgttcattg 
tgcatgcatt tatgacagcc cnccttaata 
aaaaaaaaaa aaaaaaaaaa a 
<210> SEQ ID NO 6 
<211> LENGTH: 316 
<212> TYPE: PRT 
<213> ORGANISM: Ixodes scapularis 
<400> SEQUENCE: 6 
ttttagctga tgttaaggac acttataata 
tttgngcctc tgtaanaatt gatgctcttt 
tcaagtaatc cttactcagg tgtcagatat 
agtggcaaaa ggcattgctc tttgtcacat 
aactataatg cagctaatnt gaaaaaaaaa 
Met Ala Ser Cys Gly Ala Ser Ala Thr Gly Pro Leu Val Leu Arg Val 
1 5 10 15 
Ile Ser Asn Thr Val Lys Ile Val Asn Ser Ala Gly Lys Ile Ile Lys 
20 25 30 
Asp Ile Met Asn Ser Gly Asn Leu Gly Ile Val Glu Lys Glu Gly Ile 
35 40 45 
Asn Asp Leu Gln Thr Glu Ala Asp Arg Ser Val Gln Arg Cys Ile Val 
50 55 60 
Thr Ser Leu Ser Arg Gln Phe Pro Lys Leu Thr Ile Ile Gly Glu Glu 
65 70 75 80 
Thr Leu Glu Glu Lys Lys Ile Ser Asp Asp Trp Ile Ile Thr Glu His 
85 90 95 
Asp Lys Asp Val Leu Ala Thr Ser Leu Pro Asp Asn Leu Lys Asn Ile 
100 105 110 
Lys Glu Glu Asp Leu Val Val Trp Val Asp Pro Leu Asp Gly Thr Lys 
115 120 125 
Glu Tyr Thr Gln Gly Phe Leu Asp His Val Thr Ile Leu Val Gly Ile 
130 135 140 
Ala Val Asp Gly Lys Ala Val Gly Gly Val Ile His Gln Pro Tyr Tyr 
145 150 155 160 
Asn Tyr Gln Val Glu Lys Asp Val Tyr Lys Gln Gly Arg Thr Met Trp 
165 170 175 
Gly Ile Val Gly Val Gly Ala Phe Gly Ile Ser Arg Ile Ala Pro Pro 
180 185 190 
Glu Asn Lys Arg Ile Ile Thr Thr Thr Arg Ser His Ser Ser Pro Thr 
195 200 205 
Ile Asn Ser Cys Ile Glu Ala Met Asn Pro Asp Glu Val Leu Arg Val 
210 215 220 
Gly Gly Ala Gly His Lys Val Leu Leu Leu Ile Glu Gly Lys Ala His 
225 230 235 240 
Ala Tyr Val Phe Pro Ser Lys Gly Cys Lys Lys Trp Asp Thr Cys Ala 
245 250 255 
Pro Glu Ala Ile Leu His Ala Thr Gly Gly Leu Leu Thr Asp Val His 
260 265 270 
Gly Asn Arg Leu Glu Tyr His Lys Asp Val Glu His Val Asn Ala Gly 
275 280 285 
Gly Val Leu Ala Thr Cys Leu Lys Glu Gln His Glu Trp Phe Lys Asn 
290 295 300 










<210> SEQ ID NO 7 
<211> LENGTH: 697 
<212> TYPE: DNA 
<213> ORGANISM: Ixodes scapular is 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (573) .. (573) 
<223> OTHER INFORMATION: n is a, 













<210> SEQ ID NO 8 
<211> LENGTH: 232 













<213> ORGANISM: Ixodes scapularis 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (191) .. (191) 
US 7,214,784 B2 
-continued 
315 
c, g, or t 
ttctggctca acaaggagca gtgttgctgg 60 
gactgcaagc agtggtatcg gtggcccgag 120 
gcaggctttt acctgctctc ctacctgctg 180 
ctggccgtca tgctcgttcg caccttcgcg 240 
atcaagacga ttctgagcgg cttcatcatc 300 
atcaaatcag tgtgtctggt gctggccgtc 360 
cccctggtgc acgtggcctg ctgcatcggg 420 
ggcaagaatg aggccaagaa gagggagatc 480 
gtggcctttg gggctcccat cggcggtgtt 540 
ttncccttga agacgctgtg gcgttccttc 600 
cgctccatca acccctttgg caacgaccac 660 
ccctggc 697 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE: 8 
Asp Leu Lys Glu Gly Ile Cys Pro Gln Ala Phe Trp Leu Asn Lys Glu 
1 5 10 15 
Gln Cys Cys Trp Ala Ser Asn Asp Thr Phe Phe Lys Gly Asp Asp Cys 
20 25 30 
Lys Gln Trp Tyr Arg Trp Pro Glu Met Phe Asp Ser Gly Met Asp Lys 
35 40 45 
Asp Gly Ala Gly Phe Tyr Leu Leu Ser Tyr Leu Leu Tyr Val Met Trp 
50 55 60 
Ser Val Leu Phe Ala Thr Leu Ala Val Met Leu Val Arg Thr Phe Ala 
65 70 75 80 
Pro Tyr Ala Cys Gly Ser Gly Ile Pro Glu Ile Lys Thr Ile Leu Ser 
85 90 95 
Gly Phe Ile Ile Arg Gly Tyr Leu Gly Lys Trp Thr Leu Thr Ile Lys 
100 105 110 
Ser Val Cys Leu Val Leu Ala Val Gly Ala Gly Leu Ser Leu Gly Lys 
115 120 125 
Glu Gly Pro Leu Val His Val Ala Cys Cys Ile Gly Asn Ile Phe Ser 
130 135 140 
Tyr Leu Phe Pro Lys Tyr Gly Lys Asn Glu Ala Lys Lys Arg Glu Ile 
145 150 155 160 
26 
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27 
-continued 
Leu Ser Ala Ala Ala Ala Ala Gly Val Ser Val Ala Phe Gly Ala Pro 
165 170 175 
Ile Gly Gly Val Leu Phe Ser Leu Glu Glu Val Ser Tyr Tyr Xaa Pro 
180 185 190 
Leu Lys Thr Leu Trp Arg Ser Phe Phe Cys Ala Leu Val Ala Ala Ser 
195 200 205 
Val Leu Arg Ser Ile Asn Pro Phe Gly Asn Asp His Leu Val Met Phe 
210 215 
Tyr Val Glu Tyr Asp Phe Pro Trp 
225 230 
<210> SEQ ID NO 9 
<211> LENGTH: 1221 
<212> TYPE: DNA 
<213> ORGANISM: Ixodes scapularis 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (713) .. (713) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<400> SEQUENCE: 9 
220 
gtttcttgtt acggtagtgg agtgctgagt ttactcgata atatctgaga aatagtggca 60 
atatcaattt ttctgtaaat tagaaatgta accaatggcg tggctatctt ctagtcgaca 120 
ctaacgtctc ggatctgctg ttcaaagtcc cgggcgatca agccgtattt gttgtccagc 180 
tgccaagtgc gtcgaatatg atgccgaaaa agaaagaatc agtcgcgagc tctaaagaag 240 
acgcgccgat cgacgtgatc ggcctgccct cccacaaacg acacaagaag cacaagcaca 300 
aaaagcacaa gcgcaagcga ggcacggacc aagacgaaga ccaatcgccc gccgcgagcc 360 
cgcagagcgg tggcgagggt agcagcagca agcccgcgct caagctcaag atcaagatcg 420 
gcggacagac ggtcgagaag aacgtgacca agctgaaaca gcagcggccg ccgccgccgg 480 
accctagcga agccgatctc gccgaactcc tgatgaaacc caactcgggc gatacgagcg 540 
cagacagcga tgacgaagag gaagcctggc tcgaagccct cgagtccggc aggctcgaag 600 
aggtcgacga cgagctccgc aaaatgaagg acccgaccct gatgacggcc aggcagcggg 660 
ccctgctcga gagcaagtcg cagaaggacg aggtcccggc gacggggatg gcnggcgtcc 720 
gcggagcccg tcaaagagat gtccgaggag atgattcagc ggcggatgct gcgggccaaa 780 
aagcggaagc agcaggccga agagaagaaa gagaaggaga agaagcagac gatcgagcgt 840 
ctgctcaaga agtccgactc gaggctgagg gccagcaaga agttggccaa gaagagcgat 900 
actcccaagg tgtcgctggt caacacgcag gcaggcacgc tgctctcgtt tcccgtcggc 960 
gttgcgttcc cgctgtcggc agccgtggcc caggggtacc ccgagaagac gacgtgcggc 1020 
attaagggtt gtcgtaaccc gaagaagtac tcgtgctcca agacaggcgt gcccctgtgc 1080 
agcctcgagt gctacaagac gaacatgctg cagatgtgcg tctgagcggg cagctaggct 1140 
tccgggctac agctgctcct tgtgtatatg tatataaagt cgagaatgct gaaaaaaaaa 1200 
aaaaaaaaaa aaaaaaaaaa a 1221 
<210> SEQ ID NO 10 
<211> LENGTH: 275 
<212> TYPE: PRT 
<213> ORGANISM: Ixodes scapularis 
<400> SEQUENCE: 10 
Met Met Pro Lys Lys Lys Glu Ser Val Ala Ser Ser Lys Glu Asp Ala 
28 
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29 
-continued 
5 10 15 
Pro Ile Asp Val Ile Gly Leu Pro Ser His Lys Arg His Lys Lys His 
20 25 30 
Lys His Lys Lys His Lys Arg Lys Arg Gly Thr Asp Gln Asp Glu Asp 
35 40 45 
Gln Ser Pro Ala Ala Ser Pro Gln Ser Gly Gly Glu Gly Ser Ser Ser 
50 55 60 
Lys Pro Ala Leu Lys Leu Lys Ile Lys Ile Gly Gly Gln Thr Val Glu 
65 70 75 80 
Lys Asn Val Thr Lys Leu Lys Gln Gln Arg Pro Pro Pro Pro Asp Pro 
85 90 95 
Ser Glu Ala Asp Leu Ala Glu Leu Leu Met Lys Pro Asn Ser Gly Asp 
100 105 110 
Thr Ser Ala Asp Ser Asp Asp Glu Glu Glu Ala Trp Leu Glu Ala Leu 
115 120 125 
Glu Ser Gly Arg Leu Glu Glu Val Asp Asp Glu Leu Arg Lys Met Lys 
130 135 140 
Asp Pro Thr Leu Met Thr Ala Arg Gln Arg Ala Leu Leu Glu Ser Lys 
145 150 155 160 
Ser Gln Lys Asp Glu Val Pro Ala Thr Gly Met Ala Gly Val Arg Gly 
165 170 175 
Ala Arg Gln Arg Asp Val Arg Gly Asp Asp Ser Ala Ala Asp Ala Ala 
180 185 190 
Gly Gln Lys Ala Glu Ala Ala Gly Arg Arg Glu Glu Arg Glu Gly Glu 
195 200 205 
Glu Ala Asp Asp Arg Ala Ser Ala Gln Glu Val Arg Leu Glu Ala Glu 
210 215 220 
Gly Gln Gln Glu Val Gly Gln Glu Glu Arg Tyr Ser Gln Gly Val Ala 
225 230 235 
Gly Gln His Ala Gly Arg His Ala Ala Leu Val Ser Arg Arg 
245 250 
Val Pro Ala Val Gly Ser Arg Gly Pro Gly Val Pro Arg Glu 
Val Arg His 
275 
260 
<210> SEQ ID NO 11 
<211> LENGTH: 1942 
<212> TYPE: DNA 
<213> ORGANISM: Ixodes 












tttgcggtgc agttcaacaa aaacagtttc 
cagattcccc tgcagcccaa cttcccagct 
cccgtgcaga agatggaccc cctcaccaac 
gtgttctact tcagctgcct ggtgcccatg 
gacaagcggg tgttcctggc cacctggaaa 
accctcgaca acgtcaacct cactgcagac 
attttcacga tagccaagag gaacgtggac 
ctcaccaacg gcatttgggt gttggcggag 
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31 
-continued 
gtgtacaaca aacttacgaa ctcattctac acagctgagg ctgctgtgaa tgaaactctt 600 
ctcccacccc cttcttttga tggcagtcaa tgtctcgttt cattttcttg ttttcttttg 660 
cggcgtgcta cggaacaagg tcctacattc ccaagttata tggtgttgtc gcgtaggggg 720 
cagagtgccg ctgagcccgc gacagccttg tttctgagga gagccgaacg caccacttcg 780 
aaaaagaaaa agtgaaaacg gaaaaatgaa aaattttcca gttgcttcaa attaacattc 840 
ctcgtagtca gtctgtggcc gttgagtttg gtgtaaagaa gaaaaaggtg tctcttttag 900 
tgaaaatggt tgctttttat tggtatcccc tatcacaccg agcacgaaca taagaaatcc 960 
tgacaaggat tctcctttag ttgtattatg gtggctggag cacacgaggc acctgttgcc 1020 
aattcgaccc agcaaatgcc caattctcaa gatttgagtt cattgaggtt gttttgctcc 1080 
tcccccccca ccccccaact ttgtcgttgg attgtctaac agtgtaaatg ggcgacgact 1140 
cgttattctt tttttcttca ttctttcttt ttgttgtcac gcgccccggg ggacgcgaca 1200 
caacttatgt gcataattga ttttcacagg ctgcgacgca gtctgtaaaa gaaggggaag 1260 
tgaaactctg ctccgccgct gctagtgtca tcacgggacg accatcgcgt tttctctgac 1320 
tatttaaaca aaactgcata gcttaggggg cagtctgtgc aaagtggaac aaccaaactg 1380 
agccctgccc tttcggtgtg tgtacaagca tctctgtgta acatgaacta ctttacatga 1440 
actacattgc atgaacggga gaagtttagt tgtttttttg tttttttttt caggtgacta 1500 
tgtcaacaga ttagaaccat tttttggaac ggctggaaag ataaccgctc attttgtttc 1560 
tactaaaaga ctacgaaaag tgttgacttt ttgcatcggt ttggcaacgt ttgtttggca 1620 
tgcatgtagt tgagcgtaat ggtatcaccc ctcgtaaaca ataacagtgc aatggagcag 1680 
tactgtagtg tccattaaag agcgagagtt tggttaaagg ttgttaattg aggtccgtgt 1740 
tatcctttga gtaggagagc ggcacttttt gcaaatagcg ctgctggggg cgtcatatct 1800 
gccctccaaa acatgcacat tttaagtgtg aattgttgcg gcggcttgta caagtatgtg 1860 
tgttatgtgt agaaaaagaa ctcttaatta aaatatttgt ggccaaaacg tcaaaaaaaa 1920 
aaaaaaaaaa aaaaaaaaaa aa 1942 
<210> SEQ ID NO 12 
<211> LENGTH: 191 
<212> TYPE: PRT 
<213> ORGANISM: Ixodes scapularis 
<400> SEQUENCE: 12 
Met Gln Ala Met Thr Gly Phe Ala Val Gln Phe Asn Lys Asn Ser Phe 
1 5 10 15 
Gly Leu Thr Pro Ala Gln Pro Leu Gln Leu Gln Ile Pro Leu Gln Pro 
20 25 30 
Asn Phe Pro Ala Asp Ala Ser Leu Gln Leu Gly Thr Asn Gly Pro Val 
35 40 45 
Gln Lys Met Asp Pro Leu Thr Asn Leu Gln Val Ala Ile Lys Asn Asn 
50 55 60 
Val Asp Val Phe Tyr Phe Ser Cys Leu Val Pro Met His Val Leu Ser 
65 70 75 80 
Thr Glu Asp Gly Leu Met Asp Lys Arg Val Phe Leu Ala Thr Trp Lys 
85 90 95 
Asp Ile Pro Ala Gln Asn Glu Val Gln Tyr Thr Leu Asp Asn Val Asn 
100 105 110 
Leu Thr Ala Asp Gln Val Ser Gln Lys Leu Gln Asn Asn Asn Ile Phe 
115 120 125 
32 
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33 
-continued 
Thr Ile Ala Lys Arg Asn Val Asp Gly Gln Asp Met Leu Tyr Gln Ser 
130 135 140 
Leu Lys Leu Thr Asn Gly Ile Trp Val Leu Ala Glu Leu Lys Ile Gln 
145 150 155 160 
Pro Gly Asn Pro Arg Ile Thr Leu Ser Leu Lys Thr Arg Ala Pro Glu 
165 170 175 
Val Ala Ala Gly Val Gln Gln Thr Tyr Glu Leu Ile Leu His Ser 
180 185 190 
<210> SEQ ID NO 13 
<211> LENGTH: 1428 
<212> TYPE: DNA 
<213> ORGANISM: Ixodes scapularis 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (701) .. (701) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<400> SEQUENCE: 13 
cgcgccgtgc agaagctgcg tcgggaggtt gagaaggcaa agaggaccct gtccactgct 60 
caccaggcca ggatcgagat tgaatcgttc ttcgagggag aggacttcag tgagaccctg 120 
actcgtgcta agtttgagga gctgaacatg gaccttttcc gttccaccat gaagcctgtt 180 
cagaaggtac tcgaggatgg tgacctcaag aagactgatg tggacgagat tgtgcttgtc 240 
ggaggttcca ccaggatccc caaggttcaa cagctggtca aggagttctt caatggcaag 300 
gaacccaccc gtggcatcaa ccccgacgaa gcagtcgcct acggtgccgc cgtgcaggct 360 
ggagtcctcg gcggagagga agacactggg gacctcgtgc tgttggacgt gaaccctctg 420 
accctcggca tcgagacagt gggaggcgtc atgacgaaac tgatcccccg taacacagtc 480 
atccccacga agaagtctca gatcttctcc acggcctcgg acgagcagag cactgtcacc 540 
atccaggtct ttgaggggga gcgtcccctg acaaaggaca accaccagct gggcaagttc 600 
gacctgactg gcatcccacc tgctcctcga ggtgtgcccc aaatcgaggt gaccttcgag 660 
attgacgtca acggtatcct gcgggtcagt gcagaggaca ngggtacagg caacaagcag 720 
aagatcacca tcaacaatga ccagaacagg ctgacgcctg aggacatcga gaggatggta 780 
aaggacgccg aaaagtttgc cgacgaggac aagaaggtca aggagaaggt ggaggcccgc 840 
aacgaactgg agtcttatgc ctactccctc aagaaccaga ttggagacaa ggagaagatg 900 
ggaggcaagc tctccgacga ggacaagaag actattgagc aagctgtgga cgagaaaatc 960 
aaatggctgg agcagcacag tgacgctgat gcggaagaac tcaaggaaca gaagaaacag 1020 
ctggctgata ctgtgcagcc gattgtagcc aagctgtacc ctgcaggagg caccccaccg 1080 
ccgacggaca aagatgactc tacaaaggac gagttgtaaa aacaaggcca gatctcttgg 1140 
gtacagcgaa aggcatgggg cagcagcatt atcacaagtc atctgttacg atcatgagct 1200 
catcatttca ccacctctac agtgctgctg ctgcctgcct tttggctggt tgagtgttct 1260 
tggacctatt taccatgatc attctctgta caaaaacaat tctttctgtg tttttttttt 1320 
tttcgttgta gtaacttaag ttatacagat gtcttctact gggtgggctt tctccatgag 1380 
tgggaggggg ctgggtgtca aataaaagtg tttctattaa aaaaaaaa 
<210> SEQ ID NO 14 
<211> LENGTH: 372 
<212> TYPE: PRT 
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35 
<221> NAME/KEY: misc feature 
<222> LOCATION: (234) .. (234) 
-continued 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE: 14 
Arg Ala Val Gln Lys Leu Arg Arg Glu Val Glu Lys Ala Lys Arg Thr 
1 5 10 15 
Leu Ser Thr Ala His Gln Ala Arg Ile Glu Ile Glu Ser Phe Phe Glu 
20 25 30 
Gly Glu Asp Phe Ser Glu Thr Leu Thr Arg Ala Lys Phe Glu Glu Leu 
35 40 45 
Asn Met Asp Leu Phe Arg Ser Thr Met Lys Pro Val Gln Lys Val Leu 
50 55 60 
Glu Asp Gly Asp Leu Lys Lys Thr Asp Val Asp Glu Ile Val Leu Val 
65 70 75 80 
Gly Gly Ser Thr Arg Ile Pro Lys Val Gln Gln Leu Val Lys Glu Phe 
85 90 95 
Phe Asn Gly Lys Glu Pro Thr Arg Gly Ile Asn Pro Asp Glu Ala Val 
100 105 110 
Ala Tyr Gly Ala Ala Val Gln Ala Gly Val Leu Gly Gly Glu Glu Asp 
115 120 125 
Thr Gly Asp Leu Val Leu Leu Asp Val Asn Pro Leu Thr Leu Gly Ile 
130 135 140 
Glu Thr Val Gly Gly Val Met Thr Lys Leu Ile Pro Arg Asn Thr Val 
145 150 155 160 
Ile Pro Thr Lys Lys Ser Gln Ile Phe Ser Thr Ala Ser Asp Glu Gln 
165 170 175 
Ser Thr Val Thr Ile Gln Val Phe Glu Gly Glu Arg Pro Leu Thr Lys 
180 185 190 
Asp Asn His Gln Leu Gly Lys Phe Asp Leu Thr Gly Ile Pro Pro Ala 
195 200 205 
Pro Arg Gly Val Pro Gln Ile Glu Val Thr Phe Glu Ile Asp Val Asn 
210 215 220 
Gly Ile Leu Arg Val Ser Ala Glu Asp Xaa Gly Thr Gly Asn Lys Gln 
225 230 235 240 
Lys Ile Thr Ile Asn Asn Asp Gln Asn Arg Leu Thr Pro Glu Asp Ile 
245 250 255 
Glu Arg Met Val Lys Asp Ala Glu Lys Phe Ala Asp Glu Asp Lys Lys 
260 265 270 
Val Lys Glu Lys Val Glu Ala Arg Asn Glu Leu Glu Ser Tyr Ala Tyr 
275 280 285 
Ser Leu Lys Asn Gln Ile Gly Asp Lys Glu Lys Met Gly Gly Lys Leu 
290 295 300 
Ser Asp Glu Asp Lys Lys Thr Ile Glu Gln Ala Val Asp Glu Lys Ile 
305 310 315 320 
Lys Trp Leu Glu Gln His Ser Asp Ala Asp Ala Glu Glu Leu Lys Glu 
325 330 335 
Gln Lys Lys Gln Leu Ala Asp Thr Val Gln Pro Ile Val Ala Lys Leu 
340 345 350 
Tyr Pro Ala Gly Gly Thr Pro Pro Pro Thr Asp Lys Asp Asp Ser Thr 
355 360 365 
Lys Asp Glu Leu 
370 
36 
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-continued 
<210> SEQ ID NO 15 
<211> LENGTH: 1847 
<212> TYPE: DNA 
<213> ORGANISM: Ixodes scapular is 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (1814) .. (1814) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<400> SEQUENCE: 15 
cgacgtgttt gtgagtgcag cggtgaactg gacggtgtcg tggccacgcg atggcagcgg 60 
cggtgatgaa ctgcctacgg actgcgcttt taggcgctct cgtcgtccaa ctctacgcca 120 
cgcagatagg tcaccggaaa ttcgagtaca agtacagttt caagggaccc tacctggcgc 180 
agaaggatgg atcggtgcct ttctgggagt acggcggcaa ttgcatcgcc agtgaggaga 240 
tggttcggat cacgccctcc ctgaagagca agaaaggatc catctggtcc aagctgccga 300 
catcgttccc ttggtgggag gtggagctgg tgttccgcac cacgggtacg ggcaggatag 360 
gagctgacgg cctggccttc tggtacacag acaagaagca ggcggagggt cctgtctttg 420 
gaagcagcga caagtggact ggcctggcca tcttcttcga ttccttcgac aatgataaca 480 
agcacaacaa cccatacatc atgggcatgg tgaacgatgg aacaaaagcc tacgatcatg 540 
agagtgacgg tgccaaccaa cagctagcgg gatgccagcg ggacttccgc aacaagcctt 600 
accctgtcag ggccaagata gaatacttca acaacattct cacggtgctg ttccacaacg 660 
gcaacaccaa caacgacggt gactacgaga tgtgcttccg tgcggagaac gtgttcctgc 720 
cgaccaacgg ccactttggg gtgtccgccg ccacgggggg cctggcagac gaccacgacg 780 
ccctcaagtt cctgacgacg agcctgcatg cggagggcac gcagccggcc ctggcccagg 840 
gtatggccga ctcagagaag gagaagttct ccaaggagta tgaagtatac aaggacaagc 900 
tggaaaagca gaaggaggag taccggaaga cgcacccgga ggaggccgct aagcaggcca 960 
tggagcacgg ccccgagcag gcctacgaca cgcagcagca gcgcgagctg cgccagatct 1020 
tcgagggcca gagccacaaa ttgtttgagg ggctcaaggc actgcaccgc aagctggacg 1080 
aggtgctcgg gcgccaggag cgcaccctgt cgctggtgtc ggctggcggc gccggcgtgg 1140 
ccgtgggcgg tgttccgcca ccgcagatgg gtggagtgcc gtcgctgcag aggcacgaag 1200 
cagagtccct gctgagcagc cagcgggagc tgctgcagac ggtggctcag gtcaagagct 1260 
ttgtggccga ggtgcatcaa cgcacggcca ccctgcaaca ccagggggcg ggaggcaccc 1320 
agggcctcac ggccgagcag ctgcaagtgc tccaccaggt gcgggacagc gtggccagca 1380 
tgcaccggga cgtctccaac aaccagccgc agaggactgg ctgcgcgaca tcctgtctca 1440 
gcactaccca cttcttgctg tttgcaacgt tgcagttggc tgtcacgctg ggctacttgg 1500 
tgtacaggag cagcaaagag gcggcggcca agaagttcta ctgagtgcag atctcgagcc 1560 
ttgccttgcc ctcccctccc atggagtgga ccttaacccc acagactgcc agaaaccagt 1620 
gttgccagag gagcccccct cccttcttat tgggtggggt gccacagcca tcacccattc 1680 
ttcgagacaa ggccactgtt tggggggagg ggcaagagat tcatccgggg tgcgcaacaa 1740 
aacatggccg tacagaggga ggggtgctcc agaactgggt cccagccaca tcgttgcgtg 1800 
ggagcgcctt tctncctcac tctaaaaaaa aaaaaaaaaa aaaaaaa 1847 
<210> SEQ ID NO 16 
<211> LENGTH: 497 
<212> TYPE: PRT 
<213> ORGANISM: Ixodes scapular is 
US 7,214,784 B2 
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-continued 
<400> SEQUENCE: 16 
Met Ala Ala Ala Val Met Asn Cys Leu Arg Thr Ala Leu Leu Gly Ala 
1 5 10 15 
Leu Val Val Gln Leu Tyr Ala Thr Gln Ile Gly His Arg Lys Phe Glu 
20 25 30 
Tyr Lys Tyr Ser Phe Lys Gly Pro Tyr Leu Ala Gln Lys Asp Gly Ser 
35 40 45 
Val Pro Phe Trp Glu Tyr Gly Gly Asn Cys Ile Ala Ser Glu Glu Met 
50 55 60 
Val Arg Ile Thr Pro Ser Leu Lys Ser Lys Lys Gly Ser Ile Trp Ser 
65 70 75 80 
Lys Leu Pro Thr Ser Phe Pro Trp Trp Glu Val Glu Leu Val Phe Arg 
85 90 95 
Thr Thr Gly Thr Gly Arg Ile Gly Ala Asp Gly Leu Ala Phe Trp Tyr 
100 105 110 
Thr Asp Lys Lys Gln Ala Glu Gly Pro Val Phe Gly Ser Ser Asp Lys 
115 120 125 
Trp Thr Gly Leu Ala Ile Phe Phe Asp Ser Phe Asp Asn Asp Asn Lys 
130 135 140 
His Asn Asn Pro Tyr Ile Met Gly Met Val Asn Asp Gly Thr Lys Ala 
145 150 155 160 
Tyr Asp His Glu Ser Asp Gly Ala Asn Gln Gln Leu Ala Gly Cys Gln 
165 170 175 
Arg Asp Phe Arg Asn Lys Pro Tyr Pro Val Arg Ala Lys Ile Glu Tyr 
180 185 190 
Phe Asn Asn Ile Leu Thr Val Leu Phe His Asn Gly Asn Thr Asn Asn 
195 200 205 
Asp Gly Asp Tyr Glu Met Cys Phe Arg Ala Glu Asn Val Phe Leu Pro 
210 215 220 
Thr Asn Gly His Phe Gly Val Ser Ala Ala Thr Gly Gly Leu Ala Asp 
225 230 235 240 
Asp His Asp Ala Leu Lys Phe Leu Thr Thr Ser Leu His Ala Glu Gly 
245 250 255 
Thr Gln Pro Ala Leu Ala Gln Gly Met Ala Asp Ser Glu Lys Glu Lys 
260 265 270 
Phe Ser Lys Glu Tyr Glu Val Tyr Lys Asp Lys Leu Glu Lys Gln Lys 
275 280 285 
Glu Glu Tyr Arg Lys Thr His Pro Glu Glu Ala Ala Lys Gln Ala Met 
290 295 300 
Glu His Gly Pro Glu Gln Ala Tyr Asp Thr Gln Gln Gln Arg Glu Leu 
305 310 315 320 
Arg Gln Ile Phe Glu Gly Gln Ser His Lys Leu Phe Glu Gly Leu Lys 
325 330 335 
Ala Leu His Arg Lys Leu Asp Glu Val Leu Gly Arg Gln Glu Arg Thr 
340 345 350 
Leu Ser Leu Val Ser Ala Gly Gly Ala Gly Val Ala Val Gly Gly Val 
355 360 365 
Pro Pro Pro Gln Met Gly Gly Val Pro Ser Leu Gln Arg His Glu Ala 
370 375 380 
Glu Ser Leu Leu Ser Ser Gln Arg Glu Leu Leu Gln Thr Val Ala Gln 
385 390 395 400 
Val Lys Ser Phe Val Ala Glu Val His Gln Arg Thr Ala Thr Leu Gln 
405 410 415 
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His Gln Gly Ala Gly Gly Thr Gln Gly Leu Thr Ala Glu Gln Leu Gln 
420 425 430 
Val Leu His Gln Val Arg Asp Ser Val Ala Ser Met His Arg Asp Val 
435 440 445 
Ser Asn Asn Gln Pro Gln Arg Thr Gly Cys Ala Thr Ser Cys Leu Ser 
450 455 460 
Thr Thr His Phe Leu Leu Phe Ala Thr Leu Gln Leu Ala Val Thr Leu 
465 470 475 480 
Gly Tyr Leu Val Tyr Arg Ser Ser Lys Glu Ala Ala Ala Lys Lys Phe 
485 490 495 
Tyr 
<210> SEQ ID NO 17 
<211> LENGTH: 2475 
<212> TYPE: DNA 
<213> ORGANISM: Ixodes scapularis 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (1342) .. (1342) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (1388) .. (1388) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<400> SEQUENCE: 17 
catcactagt agcgagacac gtgcgtaaaa atggggccca aaacgctgtc taagcagccc 60 
gctaaagctt cttcatccac ttccaagcgc accgccggcc ccacaataag caagcagacg 120 
gaggacagcg atgacgaagg gtcaagcagc gcctactccg acttggagga ctccgaagga 180 
gccgacagca gcgactcgaa cgatttgtcg gacacggagg cgtcggagga tgactacgat 240 
gactcccaag acgaagaaaa cacgaagatt actttgactg gggtggaggg gaaggacctt 300 
gagttgaggg ggaaggacca ggaggcaccg gtggagtctg gcaaaaggtc ggcatggcac 360 
cggcagcaag aggacgccaa ggaggacaga cgaacgcaag tggtggaaga tgaatatgcc 420 
tttgactctt ccgacgaaga ggacgttcgc aacacggttg gcaacattcc tctggagtgg 480 
tacgagcact atccgcacat cggttatgat ctggaaggca agccaatcct gaagccgcct 540 
cgggttagtg acctggacga cttcctgagg aaaatggatg accccaacta ttggaggacg 600 
gtgaaggaca agagcacggg acaggacgtt gtcctgaccg acgaagatgt ggacctgatt 660 
cagaggctgc agaaaggaca gttccccagc tcgacgactg acccttacga gccatttgag 720 
gacatctttt cgcacgagac catgatccac ccggtgacca ggcaccctcc ccagaaacgc 780 
agcttcgtgc cttcaaggat agaaaaagca atggtgtcaa agatggtgca cgcaatcaag 840 
atgggctgga tcaagccccg agtaaagaag catgacccag aaagattcag cctcctgtgg 900 
gacaaggatg actcgacagc gggcagcaat gagcgaatgc agcgccacat cccggcaccc 960 
aagatgaagc tgccgggtca tgaggagtct tacaacccgc cggccgaata cctcttcacc 1020 
gaggaagagg aggccaagtg gagagagcag gagcccgaag aacggcgcat aaacttcctg 1080 
cccgccaagt acccatgtct gcgcgcagtc ccagcctacg aacgcttcat tgaggagagg 1140 
tttgagcgct gtctggatct ctacttgtgc ccgaggcagc ggaagatgag ggtgaatgtg 1200 
gatgcagagg acctgattcc tcagctgccc aaacccaagg acctgcagcc tttcccaagc 1260 
attcagtcta ttgtctatga gggtcatacg gactgtgtcc tctgcctgtc tttggagcct 1320 





















<210> SEQ ID NO 18 
<211> LENGTH: 754 
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gaggcgcccg tgaagagcgt ggcctggtgt 
gacaagactg tttccatgct ggatgccgga 
ggacaccgag ttgtctgccc tccccgaaga 
ggagcagacg tcggcctcct ctccagagtt 
tcaccgccac ggtgtggtgc aggtgacgtg 
cacggacgag ggacaggcca ccgtgcttgt 
ctccccttca gcaaggcgaa gggcggggtg 
ttcctgctgg tggcgtgcca gcgcacagtg 
gccaagaggc tcacatccaa ttgcaagtgg 
gacaatctgc tgatcggcac gtacgagaag 
accaaaccgt accagcagct gcgcatacac 
ccgcgctatc cactgtttgc gtccgccggc 
atggtgtaca atgatttact gcaaaaccca 
catgccatca gcaagggtat gggtgtgttg 
atagtcacgg ccggagcaga cagcacgctg 
ggtgtacata gtgaatcgtc aagaccgtgc 
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 
<213> ORGANISM: Ixodes scapularis 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 







OTHER INFORMATION: Xaa 
FEATURE: 
NAME/KEY: misc_feature 
LOCATION: (453) .. (453) 




Met Gly Pro Lys Thr Leu Ser Lys Gln 
1 5 
Thr Ser Lys Arg Thr Ala Gly Pro Thr 
20 25 
any naturally occurring amino 
any naturally occurring amino 
Pro Ala Lys Ala Ser Ser Ser 
10 15 
Ile Ser Lys Gln Thr Glu Asp 
30 
Ser Asp Asp Glu Gly Ser Ser Ser Ala Tyr Ser Asp Leu Glu Asp Ser 
35 40 45 
Glu Gly Ala Asp Ser Ser Asp Ser Asn Asp Leu Ser Asp Thr Glu Ala 
50 55 60 
Ser Glu Asp Asp Tyr Asp Asp Ser Gln Asp Glu Glu Asn Thr Lys Ile 
65 70 75 80 
Thr Leu Thr Gly Val Glu Gly Lys Asp Leu Glu Leu Arg Gly Lys Asp 
85 90 95 
Gln Glu Ala Pro Val Glu Ser Gly Lys Arg Ser Ala Trp His Arg Gln 
100 105 110 
Gln Glu Asp Ala Lys Glu Asp Arg Arg Thr Gln Val Val Glu Asp Glu 























US 7,214,784 B2 
45 46 
-continued 
Tyr Ala Phe Asp Ser Ser Asp Glu Glu Asp Val Arg Asn Thr Val Gly 
130 135 140 
Asn Ile Pro Leu Glu Trp Tyr Glu His Tyr Pro His Ile Gly Tyr Asp 
145 150 155 160 
Leu Glu Gly Lys Pro Ile Leu Lys Pro Pro Arg Val Ser Asp Leu Asp 
165 170 175 
Asp Phe Leu Arg Lys Met Asp Asp Pro Asn Tyr Trp Arg Thr Val Lys 
180 185 190 
Asp Lys Ser Thr Gly Gln Asp Val Val Leu Thr Asp Glu Asp Val Asp 
195 200 205 
Leu Ile Gln Arg Leu Gln Lys Gly Gln Phe Pro Ser Ser Thr Thr Asp 
210 215 220 
Pro Tyr Glu Pro Phe Glu Asp Ile Phe Ser His Glu Thr Met Ile His 
225 230 235 240 
Pro Val Thr Arg His Pro Pro Gln Lys Arg Ser Phe Val Pro Ser Arg 
245 250 255 
Ile Glu Lys Ala Met Val Ser Lys Met Val His Ala Ile Lys Met Gly 
260 265 270 
Trp Ile Lys Pro Arg Val Lys Lys His Asp Pro Glu Arg Phe Ser Leu 
275 280 285 
Leu Trp Asp Lys Asp Asp Ser Thr Ala Gly Ser Asn Glu Arg Met Gln 
290 295 300 
Arg His Ile Pro Ala Pro Lys Met Lys Leu Pro Gly His Glu Glu Ser 
305 310 315 320 
Tyr Asn Pro Pro Ala Glu Tyr Leu Phe Thr Glu Glu Glu Glu Ala Lys 
325 330 335 
Trp Arg Glu Gln Glu Pro Glu Glu Arg Arg Ile Asn Phe Leu Pro Ala 
340 345 350 
Lys Tyr Pro Cys Leu Arg Ala Val Pro Ala Tyr Glu Arg Phe Ile Glu 
355 360 365 
Glu Arg Phe Glu Arg Cys Leu Asp Leu Tyr Leu Cys Pro Arg Gln Arg 
370 375 380 
Lys Met Arg Val Asn Val Asp Ala Glu Asp Leu Ile Pro Gln Leu Pro 
385 390 395 400 
Lys Pro Lys Asp Leu Gln Pro Phe Pro Ser Ile Gln Ser Ile Val Tyr 
405 410 415 
Glu Gly His Thr Asp Cys Val Leu Cys Leu Ser Leu Glu Pro Ala Gly 
420 425 430 
Gln Phe Phe Ala Ser Xaa Ser Glu Asp Gly Thr Val Arg Ile Trp Glu 
435 440 445 
Leu Leu Thr Gly Xaa Cys Leu Lys Lys Phe Gln Phe Glu Ala Pro Val 
450 455 460 
Lys Ser Val Ala Trp Cys Pro Val Val Val Pro Met Lys Leu Cys Val 
465 470 475 480 
Asp Lys Thr Val Ser Met Leu Asp Ala Gly Val Thr Asp Lys Leu Leu 
485 490 495 
Pro Phe Thr Thr Gly His Arg Val Val Cys Pro Pro Arg Arg Val Leu 
500 505 510 
Gly Pro Gly Gly Gly Ser Gly Val Gly Ala Asp Val Gly Leu Leu Ser 
515 520 525 
Arg Val Pro Leu Pro Gly Gly Ala Ser Ala Gly Arg Ser Pro Pro Arg 
530 535 540 
Cys Gly Ala Gly Asp Val Ala Leu Glu Gly Arg Leu Leu Cys His Cys 
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545 550 555 560 
His Gly Arg Gly Thr Gly His Arg Ala Cys Pro Ser Val Val His Ala 
565 570 575 
Ala Val Arg Arg Leu Pro Phe Ser Lys Ala Lys Gly Gly Val Ser Arg 
580 585 590 
Val Leu Phe His Pro Leu Arg Pro Phe Leu Leu Val Ala Cys Gln Arg 
595 600 605 
Thr Val Arg Val Tyr His Leu Leu Lys Gln Glu Leu Ala Lys Arg Leu 
610 615 620 
Thr Ser Asn Cys Lys Trp Ile Ser Cys Met Gly Arg Pro Pro Pro Gly 
625 630 635 640 
Asp Asn Leu Leu Ile Gly Thr Tyr Glu Lys Arg Leu Met Trp Phe Asp 
645 650 655 
Leu Asp Leu Ser Thr Lys Pro Tyr Gln Gln Leu Arg Ile His Asn Ala 
660 665 670 
Ala Ile Arg Ser Val Ala Phe His Pro Arg Tyr Pro Leu Phe Ala Ser 
675 680 685 
Ala Gly Asp Asp Arg Ser Val Ile Val Ser His Gly Met Val Tyr Asn 
690 695 700 
Asp Leu Leu Gln Asn Pro Leu Ile Val Pro Leu Arg Arg Leu Lys Asn 
705 710 715 720 
His Ala Ile Ser Lys Gly Met Gly Val Leu Asp Cys Ala Phe His Pro 
725 730 735 
His Gln Pro Trp Ile Val Thr Ala Gly Ala Asp Ser Thr Leu Arg Leu 
740 745 750 
Phe Thr 
<210> SEQ ID NO 19 
<211> LENGTH: 447 
<212> TYPE: DNA 
<213> ORGANISM: Ixodes 









<210> SEQ ID NO 20 
<211> LENGTH: 108 










<213> ORGANISM: Ixodes scapularis 















Met Leu Leu Phe Cys Pro Thr Cys Ala Asn Ile Leu Ile Val Glu Gln 
1 5 10 15 
Gly Leu Glu Cys Phe Arg Phe Ala Cys Asn Thr Cys Pro Tyr Val His 
20 25 30 
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35 40 45 
Val Asp Asp Val Leu Gly Gly Ala Ala Ala Trp Glu Asn Val Asp Ser 
50 55 60 
Thr Glu Glu Lys Cys Pro Lys Cys Gly His Glu Arg Ala Tyr Phe Met 
65 70 75 80 
Gln Ile Gln Thr Arg Ser Ala Asp Glu Pro Met Thr Thr Phe Tyr Lys 
85 90 95 
Cys Cys Asn Gln Leu Cys Gly His Gln Trp Arg Asp 
100 105 
<210> SEQ ID NO 21 
<211> LENGTH: 1567 
<212> TYPE: DNA 
<213> ORGANISM: Ixodes scapularis 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (785) .. (785) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<400> SEQUENCE: 21 
ccccccaggc gcagggcttc gttcaggtcg accagggggc cctccccgca agccccgagg 60 
agcgccacct ggcaagcatg caggtcaatg gatatgagaa ccccacctac aagtacttcg 120 
aggccaacac caactgagcg gccacgcccc caggggaggg ggaaaagggg gcggacggac 180 
gtattgtgcc tgctgcgggc tgcgggatta gctcgtcccg cgttgttccg ggagccagtt 240 
ggtttgcctc gcgtcttagg agtaggcacg gcctcccttc tgcacccggt caaggaccat 300 
ggttgttggg gacacgagcg gcgtggggcg cagccagcct gagctttggg tcccggtacc 360 
acggcaaacc gtttgttccc acccgcggaa tgaaaatttt gtttgcctca gtttctttcg 420 
aatcgagcgt cggcgccgcc tccgacagcc ccgagtgcac tctgtctgtt gcgaaagacc 480 
aatggagtag ttgacactcg ggtcgcagct cgaacaagct cccgtaaaac gctacttaac 540 
cggggccggc gaccgagcgt agagcttgct gtgcgtagtt gtggataaaa cttttttttt 600 
ttgtgtgtgt gcttggtcac agacaatggg cagcttccga cgttagccac gcgccacacg 660 
ctcgcctttg ttttcttctt ctcgcggttg tcatacttag tttccattgg cgggttaaca 720 
ttccagtccg ggcgggcgcc cccgttcagg cgcgtcctga tcaaaattga gcatttggtt 780 
gtgcngtgca tttattggcc gcagcagggg gttcccgggt gcacctggtg tcgtgacacg 840 
catgtcgtga ctttcccctc agacggttgt ccttgctcat ggctcgttca cacctctagt 900 
gctggtagtc tctgttgctt aggtttgtag gagcacacta cagcagaggg tgtcacaaag 960 
ttttctaagc tgtatataca tgaggaaaac attgcgttgc acacacgcga gtttcggcct 1020 
gtttttagtt gggacagtga acgttttttg tacaggttat tatgtagtgc ctacatttgt 1080 
atgtgccagc tgcatgtgtt ttcctgcatg tggggaagcc tccgtgctgc cccgagctgt 1140 
gtgcggcccc tcctgagttt ccatgtgcca tgtgcccagc ctagggtgaa ctgggggtgc 1200 
agatgccctt gcgcacggtg tgccccggcg agcattgtgt gtccgtaggc catcgacgct 1260 
attcatgcga aattaatgtg gtcacagctg tcattgtctc agtgaacata tcatatgtcc 1320 
aaatttgtct cccctgtcag tgtgtgcttc tcttggttct acacttgcct gcatttttgt 1380 
tagtttgccg gactgtcctt ttcggtccca ggtcgacagc aggctataac aacaattccg 1440 
gtattttcca gtatcgggtc acaccaggtg taacctattg tgcatgtagt gtaacttgag 1500 
tggaaaagct aaaataaaaa tttgcaagag tctcactaaa aaaaaaaaaa aaaaaaaaaa 1560 
aaaaaaa 1567 
50 
<210> SEQ ID NO 22 
<211> LENGTH: 44 
<212> TYPE: PRT 
51 
<213> ORGANISM: Ixodes scapularis 
<400> SEQUENCE: 22 
US 7,214,784 B2 
-continued 
Pro Gln Ala Gln Gly Phe Val Gln Val Asp Gln Gly Ala Leu Pro Ala 
5 10 15 
Ser Pro Glu Glu Arg His Leu Ala Ser Met Gln Val Asn Gly Tyr Glu 
20 25 30 
Asn Pro Thr Tyr Lys Tyr Phe Glu Ala Asn Thr Asn 
35 40 
<210> SEQ ID NO 23 
<211> LENGTH: 704 
<212> TYPE: DNA 
<213> ORGANISM: Ixodes scapular is 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (534) .. (534) 
<223> OTHER INFORMATION: n is a, 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (598) .. (598) 
<223> OTHER INFORMATION: n is a, 













<210> SEQ ID NO 24 
<211> LENGTH: 681 













<213> ORGANISM: Ixodes scapularis 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (432) .. (432) 
c, g, or t 













<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (467) .. (467) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (472) .. (472) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (481) .. (481) 









































<221> NAME/KEY: misc feature 
<222> LOCATION: (493) •• (493) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (495) •• (495) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (499) •• (499) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (507) •• (507) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (515) •• (515) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (518) •• (518) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (528) •• (528) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (533) •• (533) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (547) •• (547) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (550) •• (550) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (559) •• (559) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (565) •• (565) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (567) •• (567) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (571) •• (571) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (586) •• (586) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (593) •• (593) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (599) •• (599) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (603) •• (603) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (606) •• (606) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (611) •• (611) 
55 
<223> OTHER INFORMATION: n is a, 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (619) .. (619) 
<223> OTHER INFORMATION: n is a, 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (623) .. (623) 
<223> OTHER INFORMATION: n is a, 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (625) .. (625) 
<223> OTHER INFORMATION: n is a, 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (627) .. (627) 
<223> OTHER INFORMATION: n is a, 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (651) .. (651) 
<223> OTHER INFORMATION: n is a, 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (658) .. (658) 
<223> OTHER INFORMATION: n is a, 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (666) .. (666) 
<223> OTHER INFORMATION: n is a, 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (673) .. (674) 
<223> OTHER INFORMATION: n is a, 
<400> SEQUENCE: 24 












<210> SEQ ID NO 25 
<211> LENGTH: 720 












<213> ORGANISM: Ixodes scapularis 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (488) .. (488) 
c, g, or t 
c, g, or t 
c, g, or t 
c, g, or t 
c, g, or t 
c, g, or t 
c, g, or t 
c, g, or t 












<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (625) .. (625) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (627) .. (627) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
US 7,214,784 B2 
56 
-continued 
ttcaaacggt ttcaccaaaa 60 
agttctggct catctcggct 120 
tcagcgtcac aagcaacaag 180 
acttgaaggt gggtacgctg 240 
acacctatgt cgaaagcatc 300 
accagaggga caaactagcc 360 
ctgaccccgg ttttcagtgg 420 
catcacntga antcatcagc 480 
caagttanct tgnttacaac 540 
aatccnccgg ggnaggccng 600 
aagggagcca ntttgtcntt 660 
681 
US 7,214,784 B2 
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-continued 
<222> LOCATION: (631) •• (631) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (641) •• (641) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (680) •• (680) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (692) •• (692) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (700) •• (700) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (719) •• (719) 
<223> OTHER INFORMATION: n is a, c, g, or t 
<400> SEQUENCE: 25 
ctctcagcga ctccgacgtc caaaagcaga tcaagcacat gatggctttc 
aagccaacga aaaggcagaa gaagtagacg ccaaggcagg aagaagagtt 
aagggccgcc tggtcacgga gcaaaggctc aagatcatcg actactacac 
aagcaagttg aactgcagcg caagatccaa agctccaaca tgctgaacca 
aaggtgctga aggcgggcga ggaccacatt gcgacggtgc tggaggaggc 
ctgggggaca tcaccaggga ccaggctcgc taccaagccc tcctgcagag 
caggcactgc ttcagctcct cgagcaggag gtggtcgtcc actgccgacc 
gggctgctga acttggacac gctgagtgcc aagttcaagg aggccactgg 
aagctcantg tggagcccag cctggcttcg agcagctgcg gcggagtcga 
aggcggggca agattcgcgt ctgcaacacg ctcgagtcgc ggctggacat 
cagctttctg ccgcagatca agacngncct nttcggcagg nacccccaac 
tggactaggc gggctattgn ccccgccatt cnggccagtn agcttggacc 
What is claimed is: 
1. An isolated cDNA molecule which encodes an Ixodes 
45 
associated antigenic polypeptide, said molecule having a 
nucleoxide sequence comprising at least residues 80-575 of 
SEQ ID NO: 3. 
2. An expression vector comprising the isolated cDNA 
50 
molecule of claim 1. 














4. The isolated cDNA molecule of claim 1, wherein said 
cDNA molecule encodes a polypeptide represented by SEQ 
ID NO: 4. 
5. The isolated cDNA molecule of claim 1, wherein said 
cDNA molecule encodes a polypeptide that induces anti-
bodies specific for an amino acid sequence represented by 
SEQ ID NO: 4. 
* * * * * 
